<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trans R Soc Trop Med Hyg</journal-id><journal-id journal-id-type="iso-abbrev">Trans R Soc Trop Med Hyg</journal-id><journal-id journal-id-type="publisher-id">trstmh</journal-id><journal-title-group><journal-title>Transactions of the Royal Society of Tropical Medicine and Hygiene</journal-title></journal-title-group><issn pub-type="ppub">0035-9203</issn><issn pub-type="epub">1878-3503</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8046409</article-id><article-id pub-id-type="pmid">33537781</article-id><article-id pub-id-type="doi">10.1093/trstmh/traa184</article-id><article-id pub-id-type="publisher-id">traa184</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00860</subject><subject>AcademicSubjects/MED00290</subject></subj-group></article-categories><title-group><article-title>
<italic>In vitro</italic> susceptibility testing for black grain eumycetoma causative agents</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>van de Sande</surname><given-names>Wendy W J</given-names></name><!--<email>w.vandesande@erasmusmc.nl</email>--><aff>
<institution>Erasmus Medical Center, University Medical Center Rotterdam, Department of Medical Microbiology and Infectious Diseases</institution>, P.O. Box 2040, 3000 CA Rotterdam, <country country="NL">The Netherlands</country></aff><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><author-notes><corresp id="cor1">Correspondent author: Tel: 0031-10-7033510; E-mail: <email>w.vandesande@erasmusmc.nl</email></corresp></author-notes><pub-date pub-type="collection"><month>4</month><year>2021</year></pub-date><pub-date pub-type="epub" iso-8601-date="2021-02-03"><day>03</day><month>2</month><year>2021</year></pub-date><pub-date pub-type="pmc-release"><day>03</day><month>2</month><year>2021</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>115</volume><issue>4</issue><fpage>343</fpage><lpage>354</lpage><history><date date-type="received"><day>12</day><month>10</month><year>2020</year></date><date date-type="rev-recd"><day>30</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>21</day><month>12</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2021. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.</copyright-statement><copyright-year>2020</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="pmc" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p></license></permissions><self-uri xlink:href="traa184.pdf"/><abstract><title>Abstract</title><p>Eumycetoma is a neglected tropical implantation mycosis characterized by large subcutaneous swellings. Inside the infected tissue, the causative agents are found in grains. The most common causative agents form black grains and are sterile upon isolation. <italic>In vitro</italic> susceptibility assays were developed for eumycetoma causative agents. They were based on the Clinical and Laboratory Standards Institute M38A protocol and modified to enable the use of hyphae as a starting inoculum. To ease endpoint reading, viability dyes such as resazurin or XTT have been used. So far the <italic>in vitro</italic> susceptibility assays developed have mainly been used to establish if causative agents are inhibited in growth by various antifungal agents, but not for clinical decision making. For drug discovery, the assay proved useful in determining which compounds were able to prevent hyphal growth. However, a clear correlation between <italic>in vitro</italic> inhibition in terms of the half maximal inhibitory concentration or 50% minimum inhibitory concentration (MIC50) and therapeutic efficacy assayed in a novel model system in terms of <italic>Galleria mellonella</italic> larval survival was not found. For clinical decision making, a range of MICs were found for each antifungal agent. However, no clinical breakpoints have been established for any of the causative agents. For itraconazole, the MIC50 of most causative agents was below the attainable serum levels, which might indicate that they are susceptible. However, before <italic>in vitro</italic> susceptibility can be used in clinical decision making for mycetoma, a correlation between MIC and clinical outcome needs to be made.</p></abstract><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Dutch Scientific Organisation</institution></institution-wrap></funding-source></award-group></funding-group><counts><page-count count="12"/></counts></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Mycetoma is a chronic granulomatous infectious disease of the subcutaneous tissue. It is characterized by tumorous lesions and malformation of the infected limbs.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> It can be caused by a large number of various agents.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> These causative agents can be bacteria (actinomycetoma) or fungi (eumycetoma).<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Characteristic of mycetoma is that the causative agent organizes itself in a grain inside the human tissue and the colour of the grain is dependent on the causative agent. In this grain, the bacterial filaments or fungal hyphae are packed tightly together. Depending on the causative agent, cement material can be found surrounding the filaments or hyphae that protects them from the hostile environment in the host. Globally, eumycetoma is more common than actinomycetoma<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> and the most common eumycetoma causative agents are <italic>Madurella mycetomatis</italic> (75.1%)<italic>, Falciformispora senegalensis</italic> (6.2%)<italic>, Trematosphaeria grisea</italic> (4.3%)<italic>, Scedosporium apiospermum</italic> complex (3.1%) and <italic>Medicopsis romeroi</italic> (0.8%).<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Of these causative agents, <italic>M. mycetomatis, F. senegalensis, T. grisea</italic> and <italic>M. romeroi</italic> form black grains while <italic>S. apiospermum</italic> complex forms white grains.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref></p><p>Eumycetoma is treated with a combination of antifungal agents and surgery. The treatment chosen is not dependent on the species identification. To treat eumycetoma, most commonly the regimen from the Mycetoma Research Centre in Khartoum, Sudan is used. In this regimen, the patient is treated with 200&#x02013;400&#x000a0;mg itraconazole daily for 6&#x000a0;months to create a good fibrous capsule around the lesion, followed by wide local excision. After surgery the patient continues on 200&#x02013;400&#x000a0;mg itraconazole daily until cure is achieved.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> In regions where itraconazole is not widely available, terbinafine is used as an alternative. In that case, eumycetoma is treated with 500&#x000a0;mg terbinafine twice daily and then surgery.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref></p><p>For fungal infections caused by <italic>Candida</italic>, <italic>Cryptococcus</italic> and <italic>Aspergillus</italic> species, antifungal susceptibility assays are routinely used to support clinicians in improving patient management and predicting treatment response.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> A correlation between the minimal inhibitory concentration (MIC) and therapeutic outcome has been established for each of these species.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> For <italic>Candida</italic>, this correlation is often called the &#x02018;90&#x02013;60&#x02019; rule, which means that infections due to susceptible <italic>Candida</italic> strains respond to appropriate antifungal therapy in approximately 90% of cases, whereas infections due to resistant strains respond in approximately 60% of cases.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> For <italic>Aspergillus</italic>, a correlation between voriconazole resistance and therapeutic failure has been found,<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> therefore <italic>in vitro</italic> susceptibility assays are used to guide patient management. For mycetoma, routine antifungal susceptibility assays are not performed and no correlation between the MIC and clinical outcome has been established to date. However, efforts are under way to determine if antifungal susceptibility assays can be of value in mycetoma management. Here I will review the development and use of the current antifungal susceptibility assays for eumycetoma causative agents.</p></sec><sec id="sec2"><title>International guidelines for antifungal susceptibility testing</title><p>For antifungal susceptibility testing, two international reference methods have been developed. These are the reference method of the Clinical and Laboratory Standards Institute (CLSI)<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> and the European Committee on Antimicrobial Susceptibility Testing (EUCAST).<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> These methods are quite similar, as they are both performed in 96-well plates, use Roswell Park Memorial Institute (RPMI) 1640 culture medium and spores or conidia as starting points and have identical incubation temperatures and times.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> In both assays, growth is read visually by the naked eye. Between these two different methods, only minor differences are found. These include the concentration of glucose within the RPMI medium (0.2% in CLSI and 2% in EUCAST), the type of microdilution plate used (U-shaped in CLSI and flat bottom in EUCAST) and the fungal inoculum used (0.4&#x000d7;10<sup>4</sup>&#x02013;5&#x000d7;10<sup>4</sup>&#x000a0;cfu/ml in CLSI and 1&#x000d7;10<sup>5</sup>&#x02013;2.5&#x000d7;10<sup>5</sup>&#x000a0;cfu/ml in EUCAST).<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> For most fungal species, good agreement between the two standard reference methodologies has been found.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> For eumycetoma causative agents, the CLSI-based reference method has been used as a template in the development of an antifungal susceptibility assay.</p></sec><sec id="sec3"><title>Hyphae vs conidia</title><p>As mentioned above, for <italic>in vitro</italic> susceptibility testing, conidia or spores are used as inocula. For <italic>M. mycetomatis</italic>, the most common causative agent of eumycetoma, only sporulates in very rare circumstances and sterile hyphae are usually obtained.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Therefore, to use conidia as a starting point is not feasible. For that reason, an alternative approach for generating a starting inoculum was needed. To assess the effect of the nature of the starting inoculum on the MIC, conidia and hyphal fragments were compared.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>&#x02013;</sup><xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> Two different approaches have been reported in the literature to generate hyphal fragments direct from a colony. The first is to generate hyphal fragments via sonication,<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> the second is by rubbing the fungal colony with a sterile scalpel or transfer tip.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> When hyphal fragments were generated from <italic>Aspergillus fumigatus</italic> by sonication and used as a starting inoculum (70&#x02013;80% transmission at 660&#x000a0;nm) in the CLSI antifungal susceptibility assay, similar MICs for amphotericin B and voriconazole were obtained compared with the conidia starting inoculum (5&#x000d7;10<sup>4</sup>&#x000a0;cfu/ml).<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> The MICs for itraconazole were one dilution step higher.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> When hyphal fragments were generated by rubbing the fungal colony and used as a starting inoculum (2&#x02013;5&#x000d7;10<sup>4</sup>&#x000a0;cfu/ml) in the EUCAST-based antifungal susceptibility assay, again similar MICs for amphotericin B, posaconazole and voriconazole were obtained.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> This was not only demonstrated for <italic>Aspergillus</italic>, but also for species of <italic>Absidia</italic><italic>, Acremonium</italic>, <italic>Emericella</italic>, <italic>Fusarium</italic>, <italic>Microsporum</italic>, <italic>Mucor</italic>, <italic>Paecilomyces</italic>, <italic>Rhizomucor</italic>, <italic>Rhizopus</italic>, <italic>Scedosporium</italic>, <italic>Trichoderma</italic> and <italic>Trichophyton</italic>.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> Therefore hyphal fragments seem a good substitute for conidia. In contrast, when hyphal clumps instead of hyphal fragments were used as a starting inoculum, a significant increase in 50% minimum inhibitory concentration (MIC50) from 1&#x000a0;&#x000b5;g/ml (conidia) to 8&#x000a0;&#x000b5;g/ml (hyphal clumps) was noted for amphotericin B and from 0.5&#x02013;1&#x000a0;&#x000b5;g/ml (conidia) to &#x0003e;16&#x000a0;&#x000b5;g/ml (hyphal clumps) for the azoles.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> This indicated that only MICs obtained for hyphal fragments were comparable to those obtained with conidia, not those obtained with fungal clumps. The manner in which hyphal fragments were generated seemed less important as long as the same cfu/ml or density was used. Therefore, for mycetoma agents, hyphal fragments are currently generated by sonication.</p></sec><sec id="sec4"><title>Viability dyes</title><p>Since both the CLSI and EUCAST reference methods use visual endpoint reading, this becomes more complicated when the starting inoculum is already turbid.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> In the case of a hyphal suspension, this is often the case. In such cases, viability dyes detecting metabolic activity can be used as an alternative method for endpoint reading even though growth and metabolic activity are not necessarily equivalent. This is because any drug that has a direct influence on the metabolic rate could have an effect on the reduction of viability dyes even if the biomass remains the same.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref></p><p>There are several viability dyes that have been used for endpoint reading in <italic>in vitro</italic> antifungal susceptibility assays, including resazurin,<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>&#x02013;</sup><xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> tetrazolium salts<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>&#x02013;</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> and the luciferin&#x02013;luciferase bioluminescence assay<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> (Table&#x000a0;<xref rid="tbl1" ref-type="table">1</xref>). The most common dyes are resazurin and tetrazolium salts (Figure&#x000a0;<xref ref-type="fig" rid="fig1">1</xref>). Of these, resazurin is the oldest in use and also the cheapest. Furthermore, its derivative, alamarBlue, is also used in the commercial CLSI-based antifungal susceptibility assay YeastOne.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Resazurin is non-fluorescent and deep blue coloured and will be metabolically reduced by 1,4-dihydronicotinamide adenine dinucleotide (NADH) in viable cells to the fluorescent pink-coloured resorufin<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> and upon prolonged incubation to the colourless hydroresorufin.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> It can be dissolved directly in culture media and is often added at the beginning of an antifungal susceptibility assay and incubated during the assay.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> To measure the metabolic activity, resazurin and resorufin are measured fluorometrically (&#x003bb;<sub>ex</sub> 579&#x000a0;nm, &#x003bb;<sub>em</sub> 584&#x000a0;nm) or colourimetrically (resazurin, 605&#x000a0;nm; resorufin, 573&#x000a0;nm).<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> There is no need for cell lysis prior to spectrophotometric measurement, as both resazurin and resorufin diffuse freely through the fungal cell membrane.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> Although resazurin is relative cheap, it has only limited linear range that is highly dependent on the temperature, pH and initial resazurin concentration.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> Due to the prolonged incubation and the secretion of pyomelanin by <italic>M. mycetomatis</italic>, growth was observed as brown instead of pink (Figure&#x000a0;<xref ref-type="fig" rid="fig1">1</xref>A).<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> The brown pigmentation did not influence the visual endpoint reading of the MIC (Figure&#x000a0;<xref ref-type="fig" rid="fig1">1</xref>A), however, it influenced the wavelength at which reliable readings could be obtained. Therefore, for <italic>M. mycetomatis</italic>, absorbance was measured at 620&#x000a0;nm when alamarBlue was used<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> and at 600&#x000a0;nm when resazurin was used.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref></p><table-wrap id="tbl1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Viability dyes used in fungal <italic>in vitro</italic> susceptibility assays</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Viability dye</th><th align="left" rowspan="1" colspan="1">Full name</th><th align="left" rowspan="1" colspan="1">Active mechanism</th><th align="left" rowspan="1" colspan="1">Incubation during or after assay</th><th align="left" rowspan="1" colspan="1">Absorbance wavelength (nm)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Resazurin/alamarBlue</td><td rowspan="1" colspan="1">7-hydroxy-3<italic>H</italic>-phnoxazin-3-one-10-oxide sodium salt</td><td rowspan="1" colspan="1">Reduction by NADH</td><td rowspan="1" colspan="1">During</td><td rowspan="1" colspan="1">600/620</td></tr><tr><td rowspan="1" colspan="1">MTT</td><td rowspan="1" colspan="1">3-(4.5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</td><td rowspan="1" colspan="1">Reduction by NADH</td><td rowspan="1" colspan="1">After</td><td rowspan="1" colspan="1">550</td></tr><tr><td rowspan="1" colspan="1">XTT</td><td rowspan="1" colspan="1">2,3-bis(2-methyloxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2<italic>H</italic>-tetrazolium hydroxide</td><td rowspan="1" colspan="1">Reduction by NADH</td><td rowspan="1" colspan="1">After</td><td rowspan="1" colspan="1">450</td></tr><tr><td rowspan="1" colspan="1">WST-8</td><td rowspan="1" colspan="1">2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl-5-(2.4-disulfophenyl)-2<italic>H</italic>-tetrazolium monosodium salt</td><td rowspan="1" colspan="1">Reduction by NADH</td><td rowspan="1" colspan="1">After</td><td rowspan="1" colspan="1">460</td></tr><tr><td rowspan="1" colspan="1">Luciferase/luciferin</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">ATP</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">560</td></tr></tbody></table></table-wrap><fig id="fig1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Viability dyes used with <italic>M. mycetomatis.</italic> As an example, an <italic>in vitro</italic> susceptibility assay with itraconazole is used. (<bold>A</bold>) The visual appearance of the wells and the calculated growth percentages obtained with alamarBlue, a resazurin derivative. The well on the far left indicates the growth control, followed by various concentrations of itraconazole. The isolates used produced pyomelanin, therefore a brown colour is seen. The well on the far left is the negative control, which is blue in the case of amphotericin B or light purple in the case of itraconazole. Different shades of brown or pink indicate different percentages of growth. These differences are also noted when the growth is calculated relative to the growth and negative controls. Typically growth percentages range from 0 to 100%. The MIC is considered the first well, which has a growth percentage &#x0003c;20%. (<bold>B</bold>) The visual appearance of the wells and the calculated growth percentages obtained with XTT. The well on the far left indicates the growth control. A dark orange colour can be seen. The well on the far right is the negative control, in which a light orange colour is seen. Between the negative controls, different concentrations of amphotericin B or itraconazole are seen. Different shades of orange indicate different percentages of growth. Typically growth percentages range from 0 to 100%. The MIC is considered the first well, which has a growth percentage &#x0003c;20%.</p></caption><graphic xlink:href="traa184fig1"/></fig><p>The other most commonly used viability dyes are the tetrazolium salt solutions. These salt solutions are weakly coloured and change to a strong coloured solution when forming the formazan product<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> (Figure&#x000a0;<xref ref-type="fig" rid="fig1">1</xref>B). Over the years, several tetrazolium salts have been developed. For antifungal susceptibility testing, 3-(4.5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> 2,3-bis(2-methoyloxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2<italic>H</italic>-tetrazolium hydroxide (XTT)<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> and 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl-5-(2.4-disulfophenyl)-2<italic>H</italic>-tetrazolium monosodium salt (WST-8)<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> have been used. Of these tetrazolium salts, MTT is the only one able to pass the cell membrane, due to its lipophilic side groups and positive net charge;<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> XTT and WST-8 cannot. Tetrazolium salts are reduced by mitochondrial or cell plasma enzymes like oxidoreductases, dehydrogenases, oxidases and peroxidases using NADH, dihydronicotinamide-adenine dinucleotide phosphate (NADPH), succinate or pyruvate as electron donors.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> With MTT as substrate, purple needle-like formazan crystals are produced in the cell that will destroy the cell's integrity and eventually lead to cell death because they are unable to pass the cell membrane.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> To quantify the formazan production, a 30-min cell lysis step with isopropanol containing 5% 1M hydrochloric acid is needed to release the formazan dye.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> To overcome this lysis step, tetrazolium derivatives that produce water-soluble products such as XTT and WST-8 have been developed.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> The solubility was achieved by introducing negative-charged sulfone groups to the phenyl rings.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> Due to this modification, most of the dyes are unable to pass through cell membranes and the reduction of these dyes is therefore mainly performed extracellularly.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> The electron transfer necessary for reduction of the tetrazolium salts is transduced by electron mediators like menadione and 2-methyl-1,4-naphthoquinone.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> The only tetrazolium salt used in the <italic>in vitro</italic> susceptibility assays for mycetoma causative agents is XTT (Figure&#x000a0;<xref ref-type="fig" rid="fig1">1</xref>B).</p><p>To assess the effect of a drug on the metabolic percentage of the fungus, the absorbance of the negative control (NC; well containing the culture media and the solvent but not the fungus) and the positive control (PC; the well containing the culture media, the solvent and the fungus but no antifungal agent) are used to normalize. The following formulas are used:</p><p>For alamarBlue:
<disp-formula><tex-math id="M1">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$$\begin{eqnarray*}
\textit {Percentage\ metabolic\ activity\ =} \nonumber\\
\left( {\frac{{{\rm{Absorbanc}}{{\rm{e}}_{620nm}}\ {\rm{NC}} - {\rm{Absorbanc}}{{\rm{e}}_{620nm}}\ {\rm{test}}}}{{{\rm{Absorbanc}}{{\rm{e}}_{620nm}}\ {\rm{NC}} - {\rm{Absorbanc}}{{\rm{e}}_{620nm}}\ {\rm{GC}}}}*100} \right)
\end{eqnarray*}$$\end{document}</tex-math></disp-formula></p><p>For resazurin:
<disp-formula><tex-math id="M2">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$$\begin{eqnarray*}
\textit {Percentage\ metabolic\ activity\ =} \nonumber\\
\left( {\frac{{{\rm{Absorbanc}}{{\rm{e}}_{600nm}}\ {\rm{NC}} - {\rm{Absorbanc}}{{\rm{e}}_{600nm}}\ {\rm{test}}}}{{{\rm{Absorbanc}}{{\rm{e}}_{600nm}}\ {\rm{NC}} - {\rm{Absorbanc}}{{\rm{e}}_{600nm}}\ {\rm{GC}}}}*100} \right)
\end{eqnarray*}$$\end{document}</tex-math></disp-formula></p><p>For XTT:
<disp-formula><tex-math id="M3">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$$\begin{eqnarray*}
\textit {Percentage\ metabolic\ activity\ =} \nonumber\\
\left( {\frac{{\ {\rm{Absorbanc}}{{\rm{e}}_{450nm}}\ {\rm{test}} - {\rm{Absorbanc}}{{\rm{e}}_{450nm}}\ {\rm{NC}}}}{{{\rm{Absorbanc}}{{\rm{e}}_{450nm}}\ {\rm{GC}} - {\rm{Absorbanc}}{{\rm{e}}_{450nm}}\ {\rm{NC}}}}*100} \right)
\end{eqnarray*}$$\end{document}</tex-math></disp-formula></p></sec><sec id="sec5"><title>Assays developed for mycetoma causative agents</title><p>Using the methodology described above, <italic>in vitro</italic> susceptibility assays have been developed for several black grain eumycetoma causative agents.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>&#x02013;</sup><xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> These include the common causative agent <italic>M. mycetomatis,</italic> the occasional causative agents <italic>F. senegalensis</italic>, <italic>T. grisea</italic>, <italic>M. romeroi</italic> and <italic>Nigrograna mackinnonii</italic> and the rare causative agents <italic>Madurella pseudomycetomatis</italic>, <italic>Madurella fahal</italic><italic>i</italic><italic>i</italic>, <italic>Madurella tropicana</italic>, <italic>Falciformispora tompkinsii</italic>, <italic>Emarellia grisea</italic>, <italic>Emarellia paragrisea</italic>, <italic>Exophiala dermatitidis</italic> and <italic>Exophiala jeanselmei</italic>.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> For most of these causative agents, a hyphal inoculum was prepared using sonication<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>&#x02013;</sup><xref rid="bib19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>&#x02013;</sup><xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> or scraping.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> Due to differences in growth rate and growth temperature, incubation times and temperatures are dependent on the causative agent (Table&#x000a0;<xref rid="tbl2" ref-type="table">2</xref>). For slow-growing causative agents, an incubation time of 144&#x000a0;h is needed before endpoints can be read.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>&#x02013;</sup><xref rid="bib19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>&#x02013;</sup><xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> For faster-growing species, endpoints can be read after 48&#x000a0;h.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> Mycetoma causative agents belonging to the order Sordariales usually grow well at 37&#x000b0;C and therefore <italic>in vitro</italic> susceptibility assays are performed at that temperature.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> For some of the mycetoma causative agents belonging to the order Pleosporales, <italic>in vitro</italic> susceptibility needs to be performed at 30&#x000b0;C due to a lack of growth at 37&#x000b0;C.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref></p><table-wrap id="tbl2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Settings for <italic>in vitro</italic> susceptibility assays of black-grain eumycetoma causative agents</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Species</th><th align="left" rowspan="1" colspan="1">Prevalence<xref ref-type="table-fn" rid="tb2fn1"><sup>a</sup></xref></th><th align="left" rowspan="1" colspan="1">Starting inoculum</th><th align="left" rowspan="1" colspan="1">Incubation temperature (&#x000b0;C)</th><th align="left" rowspan="1" colspan="1">Incubation time (h)</th><th align="left" rowspan="1" colspan="1">Viability dye</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic>Madurella mycetomatis</italic>
</td><td rowspan="1" colspan="1">C</td><td rowspan="1" colspan="1">Hyphal fragments</td><td rowspan="1" colspan="1">35&#x02013;37</td><td rowspan="1" colspan="1">144</td><td rowspan="1" colspan="1">XTT or resazurin</td></tr><tr><td rowspan="1" colspan="1">
<italic>Falciformispora senegalensis</italic>
</td><td rowspan="1" colspan="1">O</td><td rowspan="1" colspan="1">Hyphal fragments</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">144</td><td rowspan="1" colspan="1">Resazurin</td></tr><tr><td rowspan="1" colspan="1">
<italic>Trematosphaeria grisea</italic>
</td><td rowspan="1" colspan="1">O</td><td rowspan="1" colspan="1">Hyphal fragments</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">144</td><td rowspan="1" colspan="1">Resazurin</td></tr><tr><td rowspan="1" colspan="1">
<italic>Medicopsis romeroi</italic>
</td><td rowspan="1" colspan="1">O/R</td><td rowspan="1" colspan="1">Hyphal fragments</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">Resazurin</td></tr><tr><td rowspan="1" colspan="1">
<italic>Nigrograna mackinnonii</italic>
</td><td rowspan="1" colspan="1">O/R</td><td rowspan="1" colspan="1">Hyphal fragments</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">Resazurin</td></tr><tr><td rowspan="1" colspan="1">
<italic>Madurella pseudomycetomatis</italic>
</td><td rowspan="1" colspan="1">R</td><td rowspan="1" colspan="1">Hyphal fragments</td><td rowspan="1" colspan="1">35&#x02013;37</td><td rowspan="1" colspan="1">144</td><td rowspan="1" colspan="1">Resazurin</td></tr><tr><td rowspan="1" colspan="1">
<italic>Madurella tropicana</italic>
</td><td rowspan="1" colspan="1">R</td><td rowspan="1" colspan="1">Hyphal fragments</td><td rowspan="1" colspan="1">35&#x02013;37</td><td rowspan="1" colspan="1">144</td><td rowspan="1" colspan="1">Resazurin</td></tr><tr><td rowspan="1" colspan="1">
<italic>Madurella fahalii</italic>
</td><td rowspan="1" colspan="1">R</td><td rowspan="1" colspan="1">Hyphal fragments</td><td rowspan="1" colspan="1">35&#x02013;37</td><td rowspan="1" colspan="1">144</td><td rowspan="1" colspan="1">Resazurin</td></tr><tr><td rowspan="1" colspan="1">
<italic>Falciformispora tompkinsii</italic>
</td><td rowspan="1" colspan="1">R</td><td rowspan="1" colspan="1">Hyphal fragments</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">144</td><td rowspan="1" colspan="1">Resazurin</td></tr><tr><td rowspan="1" colspan="1">
<italic>Emarellia grisea</italic>
</td><td rowspan="1" colspan="1">R</td><td rowspan="1" colspan="1">Hyphal fragments (rubbing)</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">48, 96</td><td rowspan="1" colspan="1">No viability dye</td></tr><tr><td rowspan="1" colspan="1">
<italic>Emarellia paragrisea</italic>
</td><td rowspan="1" colspan="1">R</td><td rowspan="1" colspan="1">Hyphal fragments (rubbing)</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">48, 96</td><td rowspan="1" colspan="1">No viability dye</td></tr><tr><td rowspan="1" colspan="1">
<italic>Exophiala dermatitidis</italic>
</td><td rowspan="1" colspan="1">R</td><td rowspan="1" colspan="1">conidia</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">48, 96</td><td rowspan="1" colspan="1">No viability dye</td></tr><tr><td rowspan="1" colspan="1">
<italic>Exophiala jeanselmei</italic>
</td><td rowspan="1" colspan="1">R</td><td rowspan="1" colspan="1">conidia</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">48, 96</td><td rowspan="1" colspan="1">No viability dye</td></tr><tr><td rowspan="1" colspan="1">
<italic>Pseudochaetosphaeronema larense</italic>
</td><td rowspan="1" colspan="1">R</td><td rowspan="1" colspan="1">Hyphal fragments</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">144</td><td rowspan="1" colspan="1">Resazurin</td></tr></tbody></table><table-wrap-foot><fn id="tb2fn1"><p>
<sup>a</sup>Prevalence as calculated in Ahmed et al.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> and indicated as common (C), occasional (O) or rare (R).</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec6"><title>Antifungal agents tested</title><p>The antifungal susceptibility assays developed for mycetoma causative agents have been used to screen antifungal agents indicated for the treatment of other fungal infections, antifungal combinations, herbal medicine and drug screening purposes.</p><sec id="sec6-1"><title>Antifungal agents indicated for other fungal infections</title><p>Using the CLSI-based assays, several antifungal agents have been assessed for their activity against mycetoma causative agents. These include the polyene amphotericin B; the azoles ketoconazole, itraconazole, posaconazole, fluconazole, voriconazole, isavuconazole and ravuconazole; the allylamine terbinafine; the pyrimidine analogue 5-flucytosine; the echinocandins caspofungin, anidulafunin and micafungin; and the orotomide olorofim (Table&#x000a0;<xref rid="tbl3" ref-type="table">3</xref>). Of these, the polyene amphotericin B forms pores in the ergosterol membrane, the azoles and the allylamines inhibit ergosterol synthesis at different stages, the pyrimidine analogue 5-flucytosine competes with pyrimide and the orotomide olorofim inhibits pyrimidine biosynthesis. The echinocandins inhibit 1,3-&#x003b2;-glucan synthesis (Figure&#x000a0;<xref ref-type="fig" rid="fig2">2</xref>). As can be seen in Table&#x000a0;<xref rid="tbl3" ref-type="table">3</xref>, the most common causative agent, <italic>M. mycetomatis</italic>, has low MICs for the azoles (median MIC50 0.03&#x000a0;&#x000b5;g/ml)<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> and olorofim (MIC50 0.016&#x000a0;&#x000b5;g/ml),<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> slightly higher MICs for amphotericin B (MIC50 0.5&#x000a0;&#x000b5;g/ml)<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> and terbinafine (MIC50 8&#x000a0;&#x000b5;g/ml)<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> and is not inhibited by 5-flucytosine<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> and the echinocandins.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> The lowest MICs were obtained for ravuconazole,<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> the drug currently clinically investigated.<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> The sibling species <italic>M. pseudomycetomatis</italic> and <italic>M. tropicana</italic> have a similar susceptibility profile,<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> while <italic>M. fahalii</italic> has higher MIC50s for itraconazole (MIC &#x0003e;16&#x000a0;&#x000b5;g/ml) and fluconazole (MIC &#x0003e;256&#x000a0;&#x000b5;g/ml).<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref></p><table-wrap id="tbl3" orientation="portrait" position="float"><label>Table 3.</label><caption><p>
<italic>In vitro</italic> susceptibilities of eumycetoma causative agents</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="14" rowspan="1"/><th rowspan="1" colspan="1"/></tr><tr><th rowspan="1" colspan="1"/><th align="center" colspan="14" rowspan="1">MIC50 (&#x000b5;g/ml) (range; n)</th><th rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1">Species</th><th align="left" rowspan="1" colspan="1">AMB</th><th align="left" rowspan="1" colspan="1">KTZ</th><th align="left" rowspan="1" colspan="1">ITZ</th><th align="left" rowspan="1" colspan="1">PCZ</th><th align="left" rowspan="1" colspan="1">FLZ</th><th align="left" rowspan="1" colspan="1">VCZ</th><th align="left" rowspan="1" colspan="1">ISA</th><th align="left" rowspan="1" colspan="1">RVZ</th><th align="left" rowspan="1" colspan="1">TBF</th><th align="left" rowspan="1" colspan="1">5-FC</th><th align="left" rowspan="1" colspan="1">CAS</th><th align="left" rowspan="1" colspan="1">ANI</th><th align="left" rowspan="1" colspan="1">MCF</th><th align="left" rowspan="1" colspan="1">OLO</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><th rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<italic>Madurella mycetomatis</italic>
</td><td rowspan="1" colspan="1">0.5 (&#x0003c;0.016&#x02013;4; 34)</td><td rowspan="1" colspan="1">0.06 (&#x0003c;0.03&#x02013;4; 38)</td><td rowspan="1" colspan="1">0.03 (&#x0003c;0.03&#x02013;0.5; 38)</td><td rowspan="1" colspan="1">&#x0003c;0.03 (&#x0003c;0.03&#x02013;0.125; 34)</td><td rowspan="1" colspan="1">4 (0.25&#x02013;128; 34)</td><td rowspan="1" colspan="1">0.06 (&#x0003c;0.016&#x02013;1; 34)</td><td rowspan="1" colspan="1">0.03 (&#x0003c;0.016&#x02013;0.25; 22)</td><td rowspan="1" colspan="1">0.004 (&#x0003c;0.002&#x02013;0.03; 23)</td><td rowspan="1" colspan="1">8 (1&#x02013;16; 34)</td><td rowspan="1" colspan="1">&#x0003e;64 (&#x0003e;64; 34)</td><td rowspan="1" colspan="1">64 (6&#x02013;128; 17)</td><td rowspan="1" colspan="1">&#x0003e;128 (0.5&#x02013;128; 17)</td><td rowspan="1" colspan="1">&#x0003e;128 (8&#x02013;128; 17)</td><td rowspan="1" colspan="1">0.016 (0.004&#x02013;0.125; 21)</td><td rowspan="1" colspan="1">
<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib17" ref-type="bibr">17</xref>,<xref rid="bib22" ref-type="bibr">22</xref>,<xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib31" ref-type="bibr">31</xref>,<xref rid="bib32" ref-type="bibr">32</xref>,<xref rid="bib35" ref-type="bibr">35</xref>,<xref rid="bib40" ref-type="bibr">40</xref>,<xref rid="bib42" ref-type="bibr">42</xref></td></tr><tr><td rowspan="1" colspan="1">
<italic>Madurella pseudomycetomatis</italic>
</td><td rowspan="1" colspan="1">0.5 (0.125&#x02013;1; 7)</td><td rowspan="1" colspan="1">0.03 (0.03; 1)</td><td rowspan="1" colspan="1">0.03 (0.016&#x02013;0.06; 7)</td><td rowspan="1" colspan="1">0.016 (0.008&#x02013;0.06; 7)</td><td rowspan="1" colspan="1">16 (0.125&#x02013;32; 7)</td><td rowspan="1" colspan="1">0.06 (0.008&#x02013;0.25; 7)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003e;64 (&#x0003e;64; 7)</td><td rowspan="1" colspan="1">&#x0003e;8 (&#x0003e;8; 7)</td><td rowspan="1" colspan="1">&#x0003e;8 (&#x0003e;8;7)</td><td rowspan="1" colspan="1">&#x0003e;8 (&#x0003e;8;7)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<xref rid="bib36" ref-type="bibr">36</xref>,<xref rid="bib43" ref-type="bibr">43</xref></td></tr><tr><td rowspan="1" colspan="1">
<italic>Madurella tropicana</italic>
</td><td rowspan="1" colspan="1">0.125 (0.125;1)</td><td rowspan="1" colspan="1">0.01 (0.01;1)</td><td rowspan="1" colspan="1">0.01 (0.01;1)</td><td rowspan="1" colspan="1">0.03 (0.03;1)</td><td rowspan="1" colspan="1">4 (4; 1)</td><td rowspan="1" colspan="1">0.03 (0.03; 1)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003e;64 (&#x0003e;64; 1)</td><td rowspan="1" colspan="1">&#x0003e;16 (&#x0003e;16; 1)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<xref rid="bib36" ref-type="bibr">36</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Madurella fahalii</italic>
</td><td rowspan="1" colspan="1">0.5 (0.5; 1)</td><td rowspan="1" colspan="1">2(2; 1)</td><td rowspan="1" colspan="1">&#x0003e;16 (&#x0003e;16; 1)</td><td rowspan="1" colspan="1">1 (1; 1)</td><td rowspan="1" colspan="1">&#x0003e;256 (&#x0003e;256; 1)</td><td rowspan="1" colspan="1">1 (1; 1)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003e;64 (&#x0003e;64; 1)</td><td rowspan="1" colspan="1">&#x0003e;16 (&#x0003e;16; 1)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<xref rid="bib36" ref-type="bibr">36</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Scedosporium boydii</italic>
</td><td rowspan="1" colspan="1">1 (0.25&#x02013;2; 21)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.25 (&#x0003c;0.03&#x02013;4; 21)</td><td rowspan="1" colspan="1">0.5 (ND; 30)</td><td rowspan="1" colspan="1">16 (8&#x02013;32; 21)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib44" ref-type="bibr">44</xref>,<xref rid="bib45" ref-type="bibr">45</xref></td></tr><tr><td rowspan="1" colspan="1">
<italic>Falciformispora senegalensis</italic>
</td><td rowspan="1" colspan="1">2 (2; 4)</td><td rowspan="1" colspan="1">0.5 (0.5&#x02013;1; 4)</td><td rowspan="1" colspan="1">0.125 (0.125&#x02013;0.25; 4)</td><td rowspan="1" colspan="1">0.06 (0.06&#x02013;0.25; 4)</td><td rowspan="1" colspan="1">64 (64&#x02013;128; 4)</td><td rowspan="1" colspan="1">0.25 (0.25&#x02013;0.5; 4)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib19" ref-type="bibr">19</xref></td></tr><tr><td rowspan="1" colspan="1">
<italic>Falciformispora tompkinsii</italic>
</td><td rowspan="1" colspan="1">2 (2; 3)</td><td rowspan="1" colspan="1">1 (1; 2)</td><td rowspan="1" colspan="1">0.25 (0.25; 3)</td><td rowspan="1" colspan="1">0.25 (0.25; 3)</td><td rowspan="1" colspan="1">64 (64; 3)</td><td rowspan="1" colspan="1">0.5 (0.5; 3)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">64 (64; 3)</td><td rowspan="1" colspan="1">&#x0003e;16 (&#x0003e;16; 3)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<xref rid="bib19" ref-type="bibr">19</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Tremaptosphaeria grisea</italic>
</td><td rowspan="1" colspan="1">8 (2&#x02013;16; 3)</td><td rowspan="1" colspan="1">1 (0.125&#x02013;8; 11)</td><td rowspan="1" colspan="1">0.5 (0.03&#x02013;4; 11)</td><td rowspan="1" colspan="1">0.03 (0.03&#x02013;0.25; 3)</td><td rowspan="1" colspan="1">64 (16&#x02013;64; 3)</td><td rowspan="1" colspan="1">0.25 (0.25&#x02013;0.5; 3)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">64 (16&#x02013;64; 3)</td><td rowspan="1" colspan="1">&#x0003e;16 (8&#x02013;16; 3)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib19" ref-type="bibr">19</xref>,<xref rid="bib46" ref-type="bibr">46</xref></td></tr><tr><td rowspan="1" colspan="1">
<italic>Medicopsis romeroi</italic>
</td><td rowspan="1" colspan="1">1 (0.125&#x02013;4; 14)</td><td rowspan="1" colspan="1">4 (0.125&#x02013;8; 7)</td><td rowspan="1" colspan="1">8 (0.125&#x02013;16; 16)</td><td rowspan="1" colspan="1">0.5 (0.25&#x02013;1; 5)</td><td rowspan="1" colspan="1">&#x0003e;256 (&#x0003e;256; 5)</td><td rowspan="1" colspan="1">0.25 (0.125&#x02013;0.5; 14)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">8 (8&#x02013;32; 5)</td><td rowspan="1" colspan="1">8(4&#x02013;16; 5</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib19" ref-type="bibr">19</xref>,<xref rid="bib46" ref-type="bibr">46</xref></td></tr><tr><td rowspan="1" colspan="1">
<italic>Nigrograna mackinnonii</italic>
</td><td rowspan="1" colspan="1">0.5 (0.25&#x02013;2; 10)</td><td rowspan="1" colspan="1">0.5 (0.5; 2)</td><td rowspan="1" colspan="1">0.5 (0.25&#x02013;2; 10)</td><td rowspan="1" colspan="1">0.125 (0.125&#x02013;0.25; 2)</td><td rowspan="1" colspan="1">64 (64; 2)</td><td rowspan="1" colspan="1">0.5 (0.125&#x02013;1; 10)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">8 (8&#x02013;64; 2)</td><td rowspan="1" colspan="1">16 (2&#x02013;16;10)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<xref rid="bib19" ref-type="bibr">19</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Emarellia grisea</italic>
</td><td rowspan="1" colspan="1">0.5 (0.25&#x02013;4; 5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.25 (0.06&#x02013;0.5; 5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.25 (0.125&#x02013;0.5; 5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">8 (4&#x02013;16;5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<xref rid="bib38" ref-type="bibr">38</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Emarellia paragrisea</italic>
</td><td rowspan="1" colspan="1">1 (1; 1)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.125 (0.125; 1)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.125 (0.125; 1)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">8 (8; 1)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<xref rid="bib38" ref-type="bibr">38</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Exophiala dermatitidis</italic>
</td><td rowspan="1" colspan="1">1 (0.25&#x02013;4; 51)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">1 (&#x0003c;0.015&#x02013;2; 51)</td><td rowspan="1" colspan="1">0.5 (&#x0003c;0.03&#x02013;2; 51)</td><td rowspan="1" colspan="1">32 (8&#x02013;64; 51)</td><td rowspan="1" colspan="1">0.25 (0.06&#x02013;2)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.25 (&#x0003c;0.03&#x02013;4)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<xref rid="bib47" ref-type="bibr">47</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Exophiala jeanselmei</italic>
</td><td rowspan="1" colspan="1">1 (0.25&#x02013;2; 17)</td><td rowspan="1" colspan="1">4 (1&#x02013;8; 3)</td><td rowspan="1" colspan="1">0.06 (0.015&#x02013;0.25; 17)</td><td rowspan="1" colspan="1">0.03 (0.016&#x02013;0.063; 17)</td><td rowspan="1" colspan="1">16 (8&#x02013;32; 9)</td><td rowspan="1" colspan="1">0.5 (0.125&#x02013;2; 17)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">4 (2&#x02013;8; 9)</td><td rowspan="1" colspan="1">0.5 (0.063&#x02013;4; 9)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">
<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib39" ref-type="bibr">39</xref>,<xref rid="bib42" ref-type="bibr">42</xref>,<xref rid="bib48" ref-type="bibr">48</xref></td></tr><tr><td rowspan="1" colspan="1">Blood/serum level</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003e;1&#x02013;2<xref ref-type="table-fn" rid="tb3fn1">a</xref></td><td rowspan="1" colspan="1">&#x0003e;0.5&#x02013;1.5<xref ref-type="table-fn" rid="tb3fn1">a</xref></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x0003e;1&#x02013;6<xref ref-type="table-fn" rid="tb3fn1">a</xref></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2.8&#x02013;3<xref ref-type="table-fn" rid="tb3fn2">b</xref></td><td rowspan="1" colspan="1">&#x0003e;20&#x02013;50<xref ref-type="table-fn" rid="tb3fn1">a</xref></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tb3fn0"><p>Antifungal agents abbreviated as follows: amphotericin B (AMB), ketoconazole (KTZ), itraconazole (ITZ), posaconazole (PCZ), fluconazole (FLZ), voriconazole (VCZ), isavuconazole (ISA), ravuconazole (RVZ), terbinafine (TBF), 5-flucytosine (5FC), caspofungin (CAS), anidulafungin (ANI), micafungin (MCF), olorofim (OLO).</p></fn><fn id="tb3fn1"><p>
<sup>a</sup>Thereapeutic goal according to Andes et al.<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref></p></fn><fn id="tb3fn2"><p>
<sup>b</sup>Serum level modelled by Dolton et al.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref></p></fn></table-wrap-foot></table-wrap><fig id="fig2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>
<italic>M. mycetomatis</italic> cell demonstrating the compounds with antifungal activity. The green antifungal agents are the agents that have been able to inhibit growth at the concentrations tested. These include amphotericin B, the azoles, terbinafine and olorofim. The compounds not able to inhibit growth are the echinocandins and 5-flucytosine.</p></caption><graphic xlink:href="traa184fig2"/></fig><p>Of the mycetoma causative agents belonging to the order Pleosporales, low MICs are also found for amphotericin B and the azoles and higher concentrations for 5-flucytosine and caspofungin (Table&#x000a0;<xref rid="tbl3" ref-type="table">3</xref>). However, the MICs found for the azoles are in general three to four two-fold dilution steps higher than those found for <italic>M. mycetomatis.</italic> In contrast, although <italic>Madurella</italic> sp. are not inhibited at all by 5-flucytosine, growth inhibition was noted for the Pleosporales causative agents (Table&#x000a0;<xref rid="tbl3" ref-type="table">3</xref>).</p></sec><sec id="sec6-2"><title>Combining antifungal agents</title><p>As demonstrated in the previous paragraph, <italic>M. mycetomatis</italic> is inhibited by antifungal agents belonging to the polyenes, azoles, allylamines and orotomides. The next question was if enhanced growth inhibition occurs when itraconazole is combined with an antifungal agent belonging to a different class of antifungal agents. Therefore the combinations ketoconazole&#x02013;terbinafine, itraconazole&#x02013;terbinafine and itraconazole&#x02013;olorofim have been tested. All combinations appeared to be indifferent according to the calculated Fractional inhibitory concentration index (FICI) and interaction ratio's (IR) (Table&#x000a0;<xref rid="tbl4" ref-type="table">4</xref>).<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> This indifference was confirmed <italic>in vivo</italic> in <italic>Galleria mellonella</italic> larvae. Treatment with a combination of itraconazole and terbinafine did not enhance larval survival compared with treatment with itraconazole or terbinafine alone.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> Combining amphotericin B with either itraconazole or terbinafine was antagonistic in the <italic>in vivo G. mellonella</italic> grain model.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref></p><table-wrap id="tbl4" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Combinations of antifungal agents tested for <italic>M. mycetomatis</italic></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Combination</th><th align="left" rowspan="1" colspan="1">Number of strains tested</th><th align="left" rowspan="1" colspan="1">FICI range<sup>a</sup></th><th align="left" rowspan="1" colspan="1">IR range<sup>b</sup></th><th align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">KTZ/TBF</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">0.30&#x02013;2.40 (I)</td><td rowspan="1" colspan="1">0.91&#x02013;1.02 (I)</td><td rowspan="1" colspan="1">
<xref rid="bib37" ref-type="bibr">37</xref>
</td></tr><tr><td rowspan="1" colspan="1">ITZ/TBF</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">0.82&#x02013;2.45 (I)</td><td rowspan="1" colspan="1">0.93&#x02013;1.00 (I)</td><td rowspan="1" colspan="1">
<xref rid="bib37" ref-type="bibr">37</xref>
</td></tr><tr><td rowspan="1" colspan="1">ITZ/OLO</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">3.2 (I)</td><td rowspan="1" colspan="1">0.91 (I)</td><td rowspan="1" colspan="1">
<xref rid="bib35" ref-type="bibr">35</xref>
</td></tr></tbody></table><table-wrap-foot><fn id="tb4fn1"><p>
<sup>a</sup>Fractional inhibitory concentration index (FICI) was calculated with the following formula: <inline-formula><tex-math id="M4">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\sum FIC\ = \ FICA + FICB\ = \ ( {\frac{{C_A^{combi}}}{{MIC_A^{alone}}}} ) + \frac{{C_B^{combi}}}{{MIC_B^{alone}}}\ $\end{document}</tex-math></inline-formula>, where <inline-formula><tex-math id="M5">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$C_A^{combi}$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M6">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$C_B^{combi}$\end{document}</tex-math></inline-formula> are the inhibitory concentrations of the drugs A and B in the combinations and <inline-formula><tex-math id="M7">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$MIC_A^{alone}$\end{document}</tex-math></inline-formula> and <inline-formula><tex-math id="M8">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$MIC_B^{alone}$\end{document}</tex-math></inline-formula> are the inhibitory concentrations of drugs A and B when acting individually. A FICI &#x02264;0.5 is considered synergistic (S), a FICI &#x0003e;0.5&#x02013;&#x02264;4 is indifferent (I) and a FICI &#x0003e;4 is antagonistic (A).</p></fn><fn id="tb4fn2"><p>
<sup>b</sup>The interaction ratio (IR) was calculated with the following formula: <inline-formula><tex-math id="M9">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$IR\ = \ \frac{{{I_o}}}{{{I_e}}}$\end{document}</tex-math></inline-formula>, where <italic>I</italic><sub>o</sub> is considered the observed percentage of inhibition and <italic>I</italic><sub>e</sub> is the expected percentage of inhibition for a certain combination. <italic>I</italic><sub>e</sub> is calculated as follows: <inline-formula><tex-math id="M10">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${I_e} = \ A + B - ( {\frac{{AB}}{{100}}} )$\end{document}</tex-math></inline-formula>, where <italic>A</italic> and <italic>B</italic> are the inhibition observed for compounds A and B alone. An IR &#x0003e;1.5 is considered synergistic (S), an IR between 0.5 and 1.5 is indifferent (I) and an IR &#x0003c;0.5 is antagonistic (A).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl5" orientation="portrait" position="float"><label>Table 5.</label><caption><p>
<italic>In vitro</italic> activity of essential oil and plant extracts against <italic>M. mycetomatis</italic></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Plant</th><th align="left" rowspan="1" colspan="1">Part of plant</th><th align="left" rowspan="1" colspan="1">Number of strains tested</th><th align="left" rowspan="1" colspan="1">MIC50</th><th align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic>Acacia nubica</italic>
</td><td rowspan="1" colspan="1">Crude methanol extract</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">1&#x000a0;&#x000b5;g/ml</td><td rowspan="1" colspan="1">
<xref rid="bib30" ref-type="bibr">30</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Boswellia papyrifera</italic>
</td><td rowspan="1" colspan="1">Crude methanol extract</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">1&#x000a0;&#x000b5;g/ml</td><td rowspan="1" colspan="1">
<xref rid="bib30" ref-type="bibr">30</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Boswellia papyrifera</italic>
</td><td rowspan="1" colspan="1">Essential oil</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">0.063% v/v</td><td rowspan="1" colspan="1">
<xref rid="bib52" ref-type="bibr">52</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Cinnamum verum</italic>
</td><td rowspan="1" colspan="1">Crude methanol extract</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">25&#x000a0;&#x000b5;g/ml</td><td rowspan="1" colspan="1">
<xref rid="bib30" ref-type="bibr">30</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Croton zambesicus</italic>
</td><td rowspan="1" colspan="1">Essential oil</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">0.063% v/v</td><td rowspan="1" colspan="1">
<xref rid="bib52" ref-type="bibr">52</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Cummin cyminum</italic>
</td><td rowspan="1" colspan="1">Essential oil</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">0.125% v/v</td><td rowspan="1" colspan="1">
<xref rid="bib52" ref-type="bibr">52</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Cymbopogon nervatus</italic>
</td><td rowspan="1" colspan="1">Essential oil</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">0.063% v/v</td><td rowspan="1" colspan="1">
<xref rid="bib52" ref-type="bibr">52</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Cymbopogon proximus</italic>
</td><td rowspan="1" colspan="1">Essential oil</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">0.063% v/v</td><td rowspan="1" colspan="1">
<xref rid="bib52" ref-type="bibr">52</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Cyperus rotundus</italic>
</td><td rowspan="1" colspan="1">Essential oil</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">0.125% v/v</td><td rowspan="1" colspan="1">
<xref rid="bib52" ref-type="bibr">52</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Eucalyptus camaldullensis</italic>
</td><td rowspan="1" colspan="1">Essential oil</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">0.125% v/v</td><td rowspan="1" colspan="1">
<xref rid="bib52" ref-type="bibr">52</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Eugenia caryohilus</italic>
</td><td rowspan="1" colspan="1">Crude methanol extract</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">50&#x000a0;&#x000b5;g/ml</td><td rowspan="1" colspan="1">
<xref rid="bib30" ref-type="bibr">30</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Melaleuca alternifolia</italic>
</td><td rowspan="1" colspan="1">Essential oil</td><td rowspan="1" colspan="1">34</td><td rowspan="1" colspan="1">0.063% v/v</td><td rowspan="1" colspan="1">
<xref rid="bib33" ref-type="bibr">33</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Mentha spicata</italic>
</td><td rowspan="1" colspan="1">Essential oil</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">0.063% v/v</td><td rowspan="1" colspan="1">
<xref rid="bib52" ref-type="bibr">52</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Nigella sativa</italic>
</td><td rowspan="1" colspan="1">Crude methanol extract</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">1&#x000a0;&#x000b5;g/ml</td><td rowspan="1" colspan="1">
<xref rid="bib30" ref-type="bibr">30</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Ocimum bacilicum</italic>
</td><td rowspan="1" colspan="1">Essential oil</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">0.25% v/v</td><td rowspan="1" colspan="1">
<xref rid="bib52" ref-type="bibr">52</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Piper nigrum</italic>
</td><td rowspan="1" colspan="1">Crude methanol extract</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">25&#x000a0;&#x000b5;g/ml</td><td rowspan="1" colspan="1">
<xref rid="bib30" ref-type="bibr">30</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Xylopia aethiopica</italic>
</td><td rowspan="1" colspan="1">Essential oil</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">0.063% v/v</td><td rowspan="1" colspan="1">
<xref rid="bib52" ref-type="bibr">52</xref>
</td></tr><tr><td rowspan="1" colspan="1">
<italic>Zingiber officinalis</italic>
</td><td rowspan="1" colspan="1">Crude methanol extract</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">12.5&#x000a0;&#x000b5;g/ml</td><td rowspan="1" colspan="1">
<xref rid="bib30" ref-type="bibr">30</xref>
</td></tr></tbody></table></table-wrap></sec><sec id="sec6-3"><title>Antiseptic solutions</title><p>The XTT-based antifungal susceptibility assay was also used to determine the <italic>in vitro</italic> activity of the antiseptic solutions 1% povidone iodine, 0.5% taurolidine Ringer&#x02019;s solution, 0.02% chlorhexidine and 1% hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) against 10 <italic>M. mycetomatis</italic> isolates. MICs ranged from 1:100 to &#x0003e;1:10 for 1% povidone iodine, 1:100 to 1:10 for 0.5% taurolidine Ringer&#x02019;s solution, 1:200 to &#x0003e;1:10 for 0.02% chlorhexidine and 1:200 to 1:20 for 1% H<sub>2</sub>O<sub>2</sub>.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> However, the killing time of the solutions was different. The 1% povidone iodine was able to kill <italic>M. mycetomatis</italic> within 5&#x000a0;min, while 2&#x000a0;h was needed when 0.02% chlorhexidine or 1% H<sub>2</sub>O<sub>2</sub> was used. A killing time of &#x0003e;6&#x000a0;h was needed when 0.5% taurolidine Ringer&#x02019;s solution was used.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> Since the killing time for antiseptic solutions is more important than the killing concentration, probably the most active antiseptic solution against <italic>M. mycetomatis</italic> is 1% povidone iodine.</p></sec><sec id="sec6-4"><title>Herbal compounds</title><p>
<italic>In vitro</italic> susceptibility assays can also be used to determine the activity of medicinal plants against mycetoma causative agents. So far the activity of fractions or essential oils from the following plants have been determined: <italic>Acacia nubica</italic>,<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><italic>Boswellia papyrifera</italic>,<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="bib52" ref-type="bibr"><sup>52</sup></xref><italic>Cinnamum verum</italic>,<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><italic>Croton zambesicus</italic>,<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref><italic>Cummium cymimum</italic>,<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref><italic>Cymbopogon nervatus</italic>,<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref><italic>Cymbopogon proximus</italic>,<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref><italic>Cyperus rotundus</italic>,<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref><italic>Eucalyptus camaldulensis</italic>,<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref><italic>Eugenia caryophilus</italic>,<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><italic>Melaleuca alternifolia</italic>,<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref><italic>Mentha spicata</italic>,<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref><italic>Nigella sativa</italic>,<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><italic>Ocimum bacilicum</italic>,<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref><italic>Piper nigrum</italic>,<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><italic>Xylopia aethiopica</italic><xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> and <italic>Zingiber officinalis</italic><xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> (Table&#x000a0;<xref rid="tbl5" ref-type="table">5</xref>). In general, relatively low MICs were obtained for the essential oils (MIC50 ranging from 0.063% to 0.25% v/v). The crude methanol extracts of <italic>A. nubica</italic> (MIC50 1&#x000a0;&#x000b5;g/ml), <italic>N. sativa</italic> (MIC50 1&#x000a0;&#x000b5;g/ml) and <italic>B. papyrifera</italic> (MIC50 1&#x000a0;&#x000b5;g/ml) were more active than those from <italic>E. caryophilus</italic> (MIC50 25&#x000a0;&#x000b5;g/ml), <italic>C. verum</italic> (MIC50 25&#x000a0;&#x000b5;g/ml), <italic>P. nigrum</italic> (MIC50 25&#x000a0;&#x000b5;g/ml) and <italic>Z. officinalis</italic> (MIC50 12.5&#x000a0;&#x000b5;g/ml)<italic>.</italic></p></sec><sec id="sec6-5"><title>Drug screening</title><p>The <italic>in vitro</italic> susceptibility assay for <italic>M. mycetomatis</italic> has been used to screen 1200 drug-like compounds gathered in the Medicines for Malaria Venture (MMV) Pathogen, Stasis and Pandemic boxes in the open source drug discovery program MycetOS (<ext-link ext-link-type="uri" xlink:href="https://github.com/OpenSourceMycetoma/General-Start-Here">https://github.com/OpenSourceMycetoma/General-Start-Here</ext-link>).<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> From the 1200 compounds screened, 287 inhibited the growth of <italic>M. mycetomatis</italic> at a concentration of 100&#x000a0;&#x000b5;M and 29 had a half maximal inhibitory concentration (IC50) &#x0003c;5 &#x000b5;M. These included the azoles ketoconazole, itraconazole, posaconazole, ravuconazole, isavuconazonium (isovuconazole), eberconazole, luliconazole, miconazole, bitertanol and difenoconazole; the benzimidazoles fenbendazole and carbendazim; and the strobilurins azoxystrobin and trifloxystrobin. Two of the potent hits obtained from these screenings were olorofim<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> and the fenarimol EPL-BS1246.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> For the fenarimols, 35 additional analogues were screened and an additional 4 potent fenarimols were identified: EPL-BS0178, EPL-BS0495, EPL-BS0800 and EPL-BS1025.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> The hits obtained in the screenings of the MMV boxes are currently further evaluated as potential new drugs for mycetoma.</p></sec></sec><sec id="sec7"><title>Correlation of <italic>in vitro</italic> susceptibility data with <italic>in vivo</italic> efficacy in animal models</title><p>To assess the therapeutic efficacy in experimental animal models, only two mouse studies<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref><sup>,</sup><xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> and three invertebrate studies<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="bib51" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> have been performed. All five studies investigated the therapeutic efficacy of antifungal agents against <italic>M. mycetomatis</italic>. This has not been assessed for any of the other causative agents. In each of these studies, only a single <italic>M. mycetomatis</italic> isolate was investigated. This makes it impossible to correlate the MIC of a drug with the therapeutic efficacy in an animal model.</p><p>In the two <italic>M. mycetomatis</italic> intraperitoneal murine grain models developed by Murray et al.<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref> and Ahmed et al.,<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref> the therapeutic efficacy of diamidinodiphenylamine,<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> amphotericin B<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> and itraconazole<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref> were determined. With the CLSI-based <italic>in vitro</italic> susceptibility assay, the MIC50s for amphotericin B and itraconazole were 0.5&#x000a0;&#x000b5;g/ml and 0.06&#x000a0;&#x000b5;g/ml, respectively (Table&#x000a0;<xref rid="tbl3" ref-type="table">3</xref>). Murray and Colichon<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> demonstrated that treatment of 15&#x000a0;weeks with 200&#x000a0;&#x000b5;g/day diamidinodiphenylamine did not result in a reduced number of grains compared with the non-treated control. Ahmed et al.<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref> demonstrated that in mice treated with 20&#x000a0;mg/kg itraconazole twice daily, grains were still present in five of six mice at day 21. In mice treated with 0.5&#x000a0;mg/kg amphotericin twice daily, no grains were detected in the treated mice.<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref> The therapeutic superiority was confirmed in an invertebrate <italic>G. mellonella</italic> grain model.<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref> When <italic>G. mellonella</italic> larvae were infected with 4&#x000a0;mg/larvae and treated with 5.7&#x000a0;mg/kg of either ketoconazole, itraconazole, voriconazole or posaconazole, no enhanced larval survival was noted compared with the phosphate-buffered saline&#x02013;treated control. Grains were still present after 10&#x000a0;days.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> When larvae were treated with 1&#x000a0;mg/kg amphotericin B or 7.14&#x000a0;mg/kg terbinafine or 14&#x000a0;mg/kg posaconazole, enhanced survival was noted.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> This indicated that, at least for posaconazole, a concentration-dependent effect was noted. Combining amphotericin B with either itraconazole or terbinafine resulted in antagonism.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref></p><p>Based on the observations in both the mouse model as well as in the <italic>G. mellonella</italic> model, it can be concluded that despite the higher MIC50s found for amphotericin B and terbinafine <italic>in vitro</italic>, <italic>in vivo</italic> they were superior to the azoles at the concentrations given.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> One of the reasons for this is that in the <italic>in vitro</italic> susceptibility assays, hyphae are exposed to antifungal agents, while <italic>in vivo</italic> hyphae are embedded in the mycetoma grain, which could offer the fungus protection against environmental stress. Since grains cannot be formed <italic>in vitro</italic>, direct comparison between grains and hyphae in terms of <italic>in vitro</italic> susceptibility testing can only be done when using either grains directly from patients or grains formed in animal models. Currently only one study with a direct comparison has been performed.<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> Murray and Colichon<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> compared the MIC of amphotericin B obtained with 1&#x000a0;mg <italic>M. mycetomatis</italic> hyphae with the MIC obtained from seven grains obtained from experimentally <italic>M. mycetomatis</italic>&#x02013;infected mice. The MIC obtained with <italic>M. mycetomatis</italic> hyphae was 1&#x000a0;&#x000b5;g/ml for amphotericin B, while no MIC was obtained with <italic>M. mycetomatis</italic> grains using concentrations up to 100&#x000a0;&#x000b5;g/ml. This demonstrated that the grain offered protection against amphotericin B. This was confirmed by an experiment in which five <italic>M. mycetomatis</italic> grains were immersed in 50&#x000a0;&#x000b5;g/ml amphotericin B for 24&#x000a0;h. Three of five grains were still viable even after such long exposures.<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> This indicated that the grain was difficult to penetrate by antifungal agents.</p><p>Characteristic of the <italic>M. mycetomatis</italic> grain is the presence of melanin and an extracellular matrix (cement material) that surrounds the hyphae in the grain. <italic>M. mycetomatis</italic> 1,8-dihydroxynaphthalene&#x02013;melanin did interfere with susceptibility to antifungal agents.<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> A four to five twofold dilution step increase in MIC was obtained when 250&#x000a0;&#x000b5;g/ml <italic>M. mycetomatis</italic> melanin was added in the Sensititre YeastOne <italic>in vitro</italic> susceptibility assay. This increase in MIC was only observed for ketoconazole and itraconazole. This was not found for voriconazole, fluconazole or amphotericin B.<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> For ketoconazole and itraconazole, this increase in MIC was likely due to binding of the drug to melanin. This binding most likely prevented the drug from reaching its intracellular target.<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> Along with melanin, the extracellular matrix can protect against antifungal agents. This matrix consists of proteins, chitin and polysaccharides,<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref><sup>&#x02013;</sup><xref rid="bib63" ref-type="bibr"><sup>63</sup></xref> components also found in fungal biofilms. Functionally the extracellular matrix can serve as a protective barrier against chemical and biological antimicrobial agents.<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> Some of the compounds inside the fungal extracellular matrix, such as &#x003b2;-1,3-D-glucan and extracellular DNA, can physically bind antifungal agents and thereby prevent the drugs from reaching the intended target at the surface or within the fungal cell.<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> Along with the physical barrier, the upregulation of efflux pumps and the presence of metabolically dormant cells have been implicated in the increased resistance.<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> Biofilms have been studied for the rare mycetoma causative agent <italic>Exophiala dermatitidis in vitro</italic>. For <italic>E. dermatitidis</italic> it was demonstrated that despite the use of susceptible planktonic cells in generating biofilms, the biofilm itself was completely resistant to itraconazole, voriconazole and posaconazole.<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref><sup>,</sup><xref rid="bib66" ref-type="bibr"><sup>66</sup></xref> The only antifungal agent tested that did have some activity against the <italic>E. dermatitidis</italic> biofilm was amphotericin B. A 50% reduction in fungal metabolic activity was obtained when <italic>E. dermatitidis</italic> was incubated with 1&#x02013;2&#x000a0;&#x000b5;g/ml amphotericin B, a concentration similar to the MIC obtained with planktonic cells.<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref></p><p>Besides looking at correlations between <italic>in vitro</italic> activity of standard antifungal agents and <italic>in vivo</italic> efficacy, the <italic>in vitro</italic> susceptibility assays were also used to discover novel drugs for mycetoma. For this, 1200 compounds were screened and 14 were tested in the <italic>G. mellonella</italic> grain model for therapeutic efficacy at a fixed concentration of 20&#x000a0;&#x000b5;M/larvae. The compounds evaluated <italic>in vivo</italic> were bitertanol, difenconazole, azoxystrobin, trifloxystrobin, MMV006357, MMV675968, MMV687807, MMV022478, MMV689244 (EPL-BS1246), EPL-BS0178, EPL-BS0495, EPL-BS0800 and EPL-BS1025. From these compounds, only bitertanol, MMV006357, MMV675968, MMV022478, EPL-BS0178, EPL-BS0495 and EPL-BS1025 significantly enhanced larval survival.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> As can be seen in Figure&#x000a0;<xref ref-type="fig" rid="fig3">3</xref>, no correlation between either IC50 or MIC50 and larval survival was found. This indicated that the currently used <italic>in vitro</italic> susceptibility assay can determine which compounds are able to inhibit fungal growth but the inhibiting concentration is not predictive for <italic>in vivo</italic> activity using fixed concentrations. For the fenarimol compounds, the logD value at pH 7.4 was more indicative than the IC50 or MIC50.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref></p><fig id="fig3" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Correlation between <italic>in vitro</italic> susceptibility data and percentage survival in <italic>M. mycetomatis&#x02013;</italic>infected <italic>G. mellonella</italic> larvae. (<bold>A</bold>) Correlation between IC50 (&#x000b5;M) and larval survival (%) of compounds tested for the pandemic and stasis boxes. (<bold>B</bold>) Correlation between MIC50 of compounds from the pandemic and stasis boxes (blue) or commonly used antifungal agents (red) and larval survival (%). The MIC50s for the compounds present in the pandemic and stasis box were determined in &#x000b5;M, while the MIC50s of the antifungal agents were determined in &#x000b5;g/ml.</p></caption><graphic xlink:href="traa184fig3"/></fig><sec id="sec7-1"><title>Correlation with therapeutic data in humans</title><p>Although <italic>M. mycetomatis</italic> is by far the most common causative agent for mycetoma and has more strains tested than the other species, no epidemiologic cut-off values or clinical breakpoints have been set for this or any of the other common causative agents, neither by the CLSI or the EUCAST. Therefore there is currently no correlation between the MIC or clinical failure or success. The CLSI developed clinical breakpoints only for <italic>Candida</italic>, while the EUCAST defined different method-based clinical breakpoints for both <italic>Candida</italic> and <italic>Aspergillus</italic>.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> For itraconazole, clinical breakpoints as determined by the EUCAST are 0.06&#x000a0;&#x000b5;g/ml for <italic>Candida albicans</italic> and <italic>Candida dubliniensis</italic>, 0.125&#x000a0;&#x000b5;g/ml for <italic>Candida parapsilosis</italic> and <italic>Candida tropicalis</italic> and 1&#x000a0;&#x000b5;g/ml for <italic>Aspergillus flavus</italic>, <italic>Aspergillus fumigatus</italic>, <italic>Aspergillus nidulans</italic> and <italic>Aspergillus terreus</italic>.<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref> For posaconazole, the clinical breakpoints are 0.06&#x000a0;&#x000b5;g/ml for <italic>C. albicans</italic>, <italic>C. dubliniensis</italic>, <italic>C. parapsilosis</italic> and <italic>C. tropicalis</italic> and 0.125&#x000a0;&#x000b5;g/ml for <italic>A. fumigatus</italic> and <italic>A. terreus</italic>.<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref> The MIC50s obtained for most causative agents of mycetoma are below the clinical breakpoints for the filamentous aspergilli.</p><p>Another parameter that might offer some prediction is to assess if the MICs found are above or below the serum levels obtained for each antifungal agent. For most of the antifungal agents, attainable serum levels have been determined (Table&#x000a0;<xref rid="tbl3" ref-type="table">3</xref>).<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> For itraconazole, the therapeutic goal for invasive fungal infections is to reach a blood trough level &#x0003e;1&#x02013;2&#x000a0;&#x000b5;g/ml itraconazole.<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> This is a concentration above the MIC50 for <italic>M. mycetomatis</italic>, <italic>M. pseudomycetomatis</italic>, <italic>M. tropicana</italic>, <italic>F. senegalensis</italic>, F<italic>. tomkinsii</italic>, <italic>T. grisea</italic>, <italic>N. mackinnonii</italic>, <italic>E. grisea</italic>, <italic>E. paragrisea</italic> and <italic>E. jeanselmei</italic>, but not for <italic>M. fahalii</italic> and <italic>M. romeroi</italic> (Table&#x000a0;<xref rid="tbl3" ref-type="table">3</xref>)<italic>. M. fahalii</italic> and <italic>M. romeroi</italic> both have an MIC50 for posaconazole that is attainable in serum (Table&#x000a0;<xref rid="tbl3" ref-type="table">3</xref>). For terbinafine, a serum level of 2.8&#x02013;3&#x000a0;&#x000b5;g/ml was modelled at the dosages used to treat mycetoma. This concentration is lower than the MICs determined for <italic>M. mycetomatis</italic> (Table&#x000a0;<xref rid="tbl1" ref-type="table">1</xref>)<italic>.</italic></p><p>Currently there are no linked data between MICs obtained for <italic>M. mycetomatis</italic> and clinical outcome. Furthermore, since surgery is always a component of mycetoma treatment, direct comparison between MICs and outcomes might be complicated. However, there are a few studies in which different series of patients were treated with either ketoconazole,<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref><sup>,</sup><xref rid="bib69" ref-type="bibr"><sup>69</sup></xref> itraconazole<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib70" ref-type="bibr"><sup>70</sup></xref> or terbinafine.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib71" ref-type="bibr"><sup>71</sup></xref> Of the 571 black-grain patients with a complete data set and treated with 200&#x02013;400&#x000a0;mg ketoconazole twice daily and surgery, only 321 (56.2%) were cured and 35 (6.1%) underwent an amputation.<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref> Of the 23 black-grain mycetoma patients treated with a combination of itraconazole with the antibiotics trimethoprim&#x02013;sulfamethoxazole and surgery, all were cured (100% cure rate).<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> Of the 22 black-grain mycetoma patients treated with terbinafine for which data were available until the end of treatment, 20 (90.9%) patients were cured and 2 (9.1%) had a recurrence,<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> indicating that despite an MIC above the attainable serum level, cure was possible. A comprehensive clinical trial is needed to determine if the MIC is indicative of clinical success or failure.</p></sec></sec><sec id="sec8"><title>Way forward</title><p>As reviewed here, <italic>in vitro</italic> susceptibility assays have been developed for the most common causative agents of black-grain eumycetoma. These assays have been used to establish if causative agents are inhibited in growth by various antifungal agents but not for clinical decision making. For drug discovery, the assay proved useful in determining which compounds were able to prevent hyphal growth and had a direct effect on the fungal cell. A clear correlation between <italic>in vitro</italic> inhibition in terms of IC50 or MIC50 and therapeutic efficacy in terms of <italic>G. mellonella</italic> larval survival was not found. This indicates that for drug discovery, other <italic>in vitro</italic> models are needed to predict the <italic>in vivo</italic> efficacy of a drug. These models should mimic certain properties of the mycetoma grain. As already seen, adding <italic>M. mycetomatis</italic> melanin to culture medium influenced the MICs obtained for ketoconazole and itraconazole and the formation of biofilms in <italic>E. dermatitidis</italic> also influenced the MICs for the azoles. Therefore, models mimicking various features of the mycetoma grain might overcome these shortcomings.</p><p>Before the <italic>in vitro</italic> susceptibility assays can be used for clinical decision making, they need to be assessed to determine if a correlation between MIC and clinical outcome exists. For that, large data sets are needed. In the current ongoing proof-of-concept superiority trial of fosravuconazole versus itraconazole for eumycetoma caused by <italic>M. mycetomatis</italic> in Sudan (ClinicalTrials.gov identifier: NCT03086226), <italic>in vitro</italic> susceptibility will be linked to clinical outcome and epidemiological cut-off values and break points will be determined for the early lesions included in the trial.<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> However, more extensive data are needed to verify if these break points might also be valid in extensive lesions or when other body sites are infected. Furthermore, the current <italic>in vitro</italic> susceptibility tests use sonication to prepare a hyphal inoculum and viability dyes to assess fungal growth. These might be too labour intensive and expensive in clinical settings. When a clinical correlation is established, the next step would be to assess in which ways <italic>in vitro</italic> susceptibility assays could be made more user friendly for clinical use.</p></sec></body><back><ack id="ACK1"><title>Acknowledgements</title><p>None.</p></ack><sec id="sec9"><title>Authors&#x02019; contributions</title><p>Author did literature search and drafted the manuscript.</p></sec><sec id="sec10"><title>Funding</title><p>WvdS received an Aspasia grant (015.013.033) from the Dutch Scientific Organisation to support her work.</p></sec><sec id="sec11"><title>Competing interests</title><p>None declared.</p></sec><sec id="sec12"><title>Ethical approval</title><p>Not required.</p></sec><sec sec-type="data-availability" id="sec13"><title>Data availability</title><p>In this review, data from published literature was used. Data-sets generated in the MycetOS project can be found under <ext-link ext-link-type="uri" xlink:href="https://github.com/OpenSourceMycetoma/General-Start-Here">https://github.com/OpenSourceMycetoma/General-Start-Here</ext-link>.</p></sec><ref-list id="REF1"><title>References</title><ref id="bib1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Zijlstra</surname>
<given-names>EE</given-names>
</string-name>, <string-name><surname>van de Sande</surname><given-names>WW</given-names></string-name>, <string-name><surname>Welsh</surname><given-names>O</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Mycetoma: a unique neglected tropical disease</article-title>. <source>Lancet Infect Dis</source>. <year>2016</year>;<volume>16</volume>(<issue>1</issue>):<fpage>100</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">26738840</pub-id></mixed-citation></ref><ref id="bib2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>van de Sande</surname>
<given-names>WWJ</given-names>
</string-name></person-group>. <article-title>Global burden of human mycetoma: a systematic review and meta-analysis</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2013</year>;<volume>7</volume>(<issue>11</issue>):<fpage>e2550</fpage>.<pub-id pub-id-type="pmid">24244780</pub-id></mixed-citation></ref><ref id="bib3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>van de Sande</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Fahal</surname><given-names>A</given-names></string-name>, <string-name><surname>Ahmed</surname><given-names>SA</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Closing the mycetoma knowledge gap</article-title>. <source>Med Mycol</source>. <year>2018</year>;<volume>56</volume>(<issue>Suppl 1</issue>):<fpage>153</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">28992217</pub-id></mixed-citation></ref><ref id="bib4"><label>4</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><string-name>
<surname>Ahmed</surname>
<given-names>SA</given-names>
</string-name>, <string-name><surname>De Hoog</surname><given-names>GS</given-names></string-name>, <string-name><surname>van de Sande</surname><given-names>WWJ</given-names></string-name></person-group>. <article-title>Fungi causing eumycotic mycetoma</article-title>. In: <person-group person-group-type="editor"><string-name><surname>Carroll</surname><given-names>KC</given-names></string-name>, <string-name><surname>Pfaller</surname><given-names>MA</given-names></string-name>, <string-name><surname>Landry</surname><given-names>ML</given-names></string-name><etal>et al.</etal></person-group>, editors<italic>.</italic><source>Manual of clinical microbiology</source>, <edition>12th ed</edition>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>ASM Press</publisher-name>; <year>2019</year>, p. <fpage>2261</fpage>&#x02013;<lpage>77</lpage>.</mixed-citation></ref><ref id="bib5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Welsh</surname>
<given-names>O</given-names>
</string-name>, <string-name><surname>Al-Abdely</surname><given-names>HM</given-names></string-name>, <string-name><surname>Salinas-Carmona</surname><given-names>MC</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Mycetoma medical therapy</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2014</year>;<volume>8</volume>(<issue>10</issue>):<fpage>e3218</fpage>.<pub-id pub-id-type="pmid">25330342</pub-id></mixed-citation></ref><ref id="bib6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Sow</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Ndiaye</surname><given-names>M</given-names></string-name>, <string-name><surname>Sarr</surname><given-names>L</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Mycetoma epidemiology, diagnosis management, and outcome in three hospital centres in Senegal from 2008 to 2018</article-title>. <source>PLoS One</source>. <year>2020</year>;<volume>15</volume>(<issue>4</issue>):<fpage>e0231871</fpage>.<pub-id pub-id-type="pmid">32330155</pub-id></mixed-citation></ref><ref id="bib7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Bassetti</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Vena</surname><given-names>A</given-names></string-name>, <string-name><surname>Bouza</surname><given-names>E</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Antifungal susceptibility testing in <italic>Candida</italic>, <italic>Aspergillus</italic> and <italic>Cryptococcus</italic> infections: are the MICs useful for clinicians?</article-title>
<source>Clin Microbiol Infect</source>. <year>2020</year>;<volume>26</volume>(<issue>8</issue>):<fpage>1024</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">32120042</pub-id></mixed-citation></ref><ref id="bib8"><label>8</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><collab>Clinical and Laboratory Standards Institute</collab></person-group>. <source>M38 reference method for broth dilution antifungal susceptibility testing of filamentous fungi</source>, <edition>3rd ed</edition>. <publisher-loc>Wayne, PA</publisher-loc>: <publisher-name>Clinical and Laboratory Standards Institute</publisher-name>, <year>2017</year>.</mixed-citation></ref><ref id="bib9"><label>9</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><string-name>
<surname>Arendrup</surname>
<given-names>MC</given-names>
</string-name>, <string-name><surname>Meletiadis</surname><given-names>J</given-names></string-name>, <string-name><surname>Mouton</surname><given-names>JW</given-names></string-name><etal>et al.</etal></person-group>
<source>Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds</source>. <publisher-loc>Basel, Switzerland</publisher-loc>: <publisher-name>EUCAST</publisher-name>; <year>2020</year>.</mixed-citation></ref><ref id="bib10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Al-Hatmi</surname>
<given-names>AM</given-names>
</string-name>, <string-name><surname>Normand</surname><given-names>AC</given-names></string-name>, <string-name><surname>Ranque</surname><given-names>S</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Comparative evaluation of Etest, EUCAST, and CLSI methods for amphotericin B, voriconazole, and posaconazole against clinically relevant <italic>Fusarium</italic> species</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2017</year>;<fpage>61</fpage>(<issue>1</issue>):<fpage>e01671</fpage>&#x02013;<lpage>16</lpage>.</mixed-citation></ref><ref id="bib11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Pfaller</surname>
<given-names>M</given-names>
</string-name>, <string-name><surname>Boyken</surname><given-names>L</given-names></string-name>, <string-name><surname>Hollis</surname><given-names>R</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against <italic>Aspergillus</italic> isolates</article-title>. <source>J Clin Microbiol</source>. <year>2011</year>;<volume>49</volume>(<issue>3</issue>):<fpage>1110</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">21209166</pub-id></mixed-citation></ref><ref id="bib12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Pujol</surname>
<given-names>I</given-names>
</string-name>, <string-name><surname>Fernandez-Ballart</surname><given-names>J</given-names></string-name>, <string-name><surname>Guarro</surname><given-names>J</given-names></string-name></person-group>. <article-title>Effect of inoculum form on in vitro antifungal susceptibilities of <italic>Aspergillus</italic> spp</article-title>. <source>J Antimicrob Chemother</source>. <year>2001</year>;<volume>47</volume>(<issue>5</issue>):<fpage>715</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">11328793</pub-id></mixed-citation></ref><ref id="bib13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>van de Sande</surname>
<given-names>WW</given-names>
</string-name>, <string-name><surname>Tavakol</surname><given-names>M</given-names></string-name>, <string-name><surname>van Vianen</surname><given-names>W</given-names></string-name><etal>et al.</etal></person-group>
<article-title>The effects of antifungal agents to conidial and hyphal forms of <italic>Aspergillus fumigatus</italic></article-title>. <source>Med Mycol</source>. <year>2010</year>;<volume>48</volume>(<issue>1</issue>):<fpage>48</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">20055743</pub-id></mixed-citation></ref><ref id="bib14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Risslegger</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Lass-Florl</surname><given-names>C</given-names></string-name>, <string-name><surname>Blum</surname><given-names>G</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Evaluation of a modified EUCAST fragmented-mycelium inoculum method for in vitro susceptibility testing of dermatophytes and the activity of novel antifungal agents</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2015</year>;<volume>59</volume>(<issue>6</issue>):<fpage>3675</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">25870071</pub-id></mixed-citation></ref><ref id="bib15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Schmalreck</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Willinger</surname><given-names>B</given-names></string-name>, <string-name><surname>Czaika</surname><given-names>V</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Susceptibility screening of hyphae-forming fungi with a new, easy, and fast inoculum preparation method</article-title>. <source>Mycopathologia</source>. <year>2012</year>;<volume>174</volume>(<issue>5&#x02013;6</issue>):<fpage>467</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">22864604</pub-id></mixed-citation></ref><ref id="bib16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Meletiadis</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Meis</surname><given-names>JF</given-names></string-name>, <string-name><surname>Mouton</surname><given-names>JW</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Comparison of NCCLS and 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl-2<italic>H</italic>-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method</article-title>. <source>J Clin Microbiol</source>. <year>2000</year>;<volume>38</volume>(<issue>8</issue>):<fpage>2949</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">10921957</pub-id></mixed-citation></ref><ref id="bib17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>van de Sande</surname>
<given-names>WWJ</given-names>
</string-name>, <string-name><surname>Luijendijk</surname><given-names>A</given-names></string-name>, <string-name><surname>Ahmed</surname><given-names>AO</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Testing of the in vitro susceptibilities of <italic>Madurella mycetomatis</italic> to six antifungal agents by using the Sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2<italic>H</italic>-tetrazolium hydroxide (XTT) assay and a modified NCCLS method</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2005</year>;<volume>49</volume>(<issue>4</issue>):<fpage>1364</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">15793113</pub-id></mixed-citation></ref><ref id="bib18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Nyuykonge</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Croughs</surname><given-names>PD</given-names></string-name>, <string-name><surname>Fahal</surname><given-names>AH</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Pyomelanin secretion in <italic>Madurella mycetomatis</italic> interferes with spectrophotometric endpoint reading using the Sensititre YeastOne alamarBlue assay but not with visual endpoint reading</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2019</year>;<volume>64</volume>(<issue>1</issue>):<fpage>e01532</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">31611353</pub-id></mixed-citation></ref><ref id="bib19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Ahmed</surname>
<given-names>SA</given-names>
</string-name>, <string-name><surname>de Hoog</surname><given-names>GS</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>DA</given-names></string-name><etal>et al.</etal></person-group>
<article-title>In vitro antifungal susceptibility of coelomycete agents of black grain eumycetoma to eight antifungals</article-title>. <source>Med Mycol</source>. <year>2015</year>;<volume>53</volume>(<issue>3</issue>):<fpage>295</fpage>&#x02013;<lpage>301</lpage>.<pub-id pub-id-type="pmid">25631481</pub-id></mixed-citation></ref><ref id="bib20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Abd Algaffar</surname>
<given-names>SO</given-names>
</string-name>, <string-name><surname>Verbon</surname><given-names>A</given-names></string-name>, <string-name><surname>van de Sande</surname><given-names>WWJ</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Development and validation of an in vitro resazurin-based susceptibility assay against <italic>Madurella mycetomatis</italic></article-title>. <source>Antimicrob Agents Chemother</source>. <year>2020</year>; <comment>doi: 10.1128/AAC.01338-20</comment>.</mixed-citation></ref><ref id="bib21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Meletiadis</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Mouton</surname><given-names>JW</given-names></string-name>, <string-name><surname>Meis</surname><given-names>JF</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis[2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2<italic>H</italic>-tetrazolium-hydroxide], for antifungal susceptibility testing of <italic>Aspergillus</italic> species</article-title>. <source>J Clin Microbiol</source>. <year>2001</year>;<volume>39</volume>(<issue>12</issue>):<fpage>4256</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">11724829</pub-id></mixed-citation></ref><ref id="bib22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Ahmed</surname>
<given-names>AO</given-names>
</string-name>, <string-name><surname>van de Sande</surname><given-names>WWJ</given-names></string-name>, <string-name><surname>van Vianen</surname><given-names>W</given-names></string-name><etal>et al.</etal></person-group>
<article-title>
<italic>In vitro</italic> susceptibilities of <italic>Madurella mycetomatis</italic> to itraconazole and amphotericin B assessed by a modified NCCLS method and a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2<italic>H</italic>-tetrazolium hydroxide (XTT) assay</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2004</year>;<volume>48</volume>(<issue>7</issue>):<fpage>2742</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">15215141</pub-id></mixed-citation></ref><ref id="bib23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Tsukatani</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Suenaga</surname><given-names>H</given-names></string-name>, <string-name><surname>Shiga</surname><given-names>M</given-names></string-name><etal>et al.</etal></person-group>
<article-title>A rapid microplate method for the proliferation assay of fungi and the antifungal susceptibility testing using the colorimetric microbial viability assay</article-title>. <source>Lett Appl Microbiol</source>. <year>2014</year>;<volume>59</volume>(<issue>2</issue>):<fpage>184</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">24713101</pub-id></mixed-citation></ref><ref id="bib24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Prabst</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Engelhardt</surname><given-names>H</given-names></string-name>, <string-name><surname>Ringgeler</surname><given-names>S</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Basic colorimetric proliferation assays: MTT, WST, and resazurin</article-title>. <source>Methods Mol Biol</source>. <year>2017</year>;<volume>1601</volume>:<fpage>1</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">28470513</pub-id></mixed-citation></ref><ref id="bib25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Yoshida</surname>
<given-names>T</given-names>
</string-name>, <string-name><surname>Uchida</surname><given-names>K</given-names></string-name>, <string-name><surname>Yamaguchi</surname><given-names>H</given-names></string-name></person-group>. <article-title>An ATP bioluminescence assay applicable to rapid fluconazole susceptibility testing of dermatophytes</article-title>. <source>Microbiol Immunol</source>. <year>1997</year>;<volume>41</volume>(<issue>5</issue>):<fpage>377</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">9194036</pub-id></mixed-citation></ref><ref id="bib26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>O'Brien</surname>
<given-names>J</given-names>
</string-name>, <string-name><surname>Wilson</surname><given-names>I</given-names></string-name>, <string-name><surname>Orton</surname><given-names>T</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity</article-title>. <source>Eur J Biochem</source>. <year>2000</year>;<volume>267</volume>(<issue>17</issue>):<fpage>5421</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">10951200</pub-id></mixed-citation></ref><ref id="bib27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Hawser</surname>
<given-names>SP</given-names>
</string-name>, <string-name><surname>Norris</surname><given-names>H</given-names></string-name>, <string-name><surname>Jessup</surname><given-names>CJ</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2<italic>H</italic>-tetrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents</article-title>. <source>J Clin Microbiol</source>. <year>1998</year>;<volume>36</volume>(<issue>5</issue>):<fpage>1450</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">9574729</pub-id></mixed-citation></ref><ref id="bib28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Ahmed</surname>
<given-names>SA</given-names>
</string-name>, <string-name><surname>Kloezen</surname><given-names>W</given-names></string-name>, <string-name><surname>Duncanson</surname><given-names>F</given-names></string-name><etal>et al.</etal></person-group>
<article-title>
<italic>Madurella mycetomatis</italic> is highly susceptible to ravuconazole</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2014</year>;<volume>8</volume>(<issue>6</issue>):<fpage>e2942</fpage>.<pub-id pub-id-type="pmid">24945848</pub-id></mixed-citation></ref><ref id="bib29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Eadie</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Fahal</surname><given-names>A</given-names></string-name>, <string-name><surname>van de Sande</surname><given-names>WWJ</given-names></string-name></person-group>. <article-title>In vitro activity of antiseptic solutions against <italic>Madurella mycetomatis,</italic> implications on eumycetoma management</article-title>. <source>Br J Dermatol</source>. <year>2015</year>;<volume>172</volume>:<fpage>1657</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">25429729</pub-id></mixed-citation></ref><ref id="bib30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Elfadil</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Fahal</surname><given-names>A</given-names></string-name>, <string-name><surname>Kloezen</surname><given-names>W</given-names></string-name><etal>et al.</etal></person-group>
<article-title>The in vitro antifungal activity of Sudanese medicinal plants against <italic>Madurella mycetomatis</italic>, the eumycetoma major causative agent</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2015</year>;<volume>9</volume>(<issue>3</issue>):<fpage>e0003488</fpage>.<pub-id pub-id-type="pmid">25768115</pub-id></mixed-citation></ref><ref id="bib31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Kloezen</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Meis</surname><given-names>JF</given-names></string-name>, <string-name><surname>Curfs-Breuker</surname><given-names>I</given-names></string-name><etal>et al.</etal></person-group>
<article-title>In vitro antifungal activity of isavuconazole to <italic>Madurella mycetomatis</italic></article-title>. <source>Antimicrob Agents Chemother</source>. <year>2012</year>;<volume>56</volume>(<issue>11</issue>):<fpage>6054</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">22964246</pub-id></mixed-citation></ref><ref id="bib32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>van Belkum</surname>
<given-names>A</given-names>
</string-name>, <string-name><surname>Fahal</surname><given-names>AH</given-names></string-name>, <string-name><surname>van de Sande</surname><given-names>WW</given-names></string-name></person-group>. <article-title>In vitro susceptibility of <italic>Madurella mycetomatis</italic> to posaconazole and terbinafine</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2011</year>;<volume>55</volume>(<issue>4</issue>):<fpage>1771</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">21263050</pub-id></mixed-citation></ref><ref id="bib33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>van de Sande</surname>
<given-names>WW</given-names>
</string-name>, <string-name><surname>Fahal</surname><given-names>AH</given-names></string-name>, <string-name><surname>Riley</surname><given-names>TV</given-names></string-name><etal>et al.</etal></person-group>
<article-title>In vitro susceptibility of <italic>Madurella mycetomatis</italic>, prime agent of Madura foot, to tea tree oil and artemisinin</article-title>. <source>J Antimicrob Chemother</source>. <year>2007</year>;<volume>59</volume>(<issue>3</issue>):<fpage>553</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">17324961</pub-id></mixed-citation></ref><ref id="bib34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Lim</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Melse</surname><given-names>Y</given-names></string-name>, <string-name><surname>Konings</surname><given-names>M</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Addressing the most neglected diseases through an open research model: the discovery of fenarimols as novel drug candidates for eumycetoma</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2018</year>;<volume>12</volume>(<issue>4</issue>):<fpage>e0006437</fpage>.<pub-id pub-id-type="pmid">29698504</pub-id></mixed-citation></ref><ref id="bib35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Lim</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Eadie</surname><given-names>K</given-names></string-name>, <string-name><surname>Konings</surname><given-names>M</given-names></string-name><etal>et al.</etal></person-group>
<article-title>
<italic>Madurella mycetomatis</italic>, the main causative agent of eumycetoma, is highly susceptible to olorofim</article-title>. <source>J Antimicrob Chemother</source>. <year>2020</year>;<volume>75</volume>(<issue>4</issue>):<fpage>936</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">31904836</pub-id></mixed-citation></ref><ref id="bib36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>de Hoog</surname>
<given-names>GS</given-names>
</string-name>, <string-name><surname>van Diepeningen</surname><given-names>AD</given-names></string-name>, <string-name><surname>Mahgoub el</surname><given-names>S</given-names></string-name><etal>et al.</etal></person-group>
<article-title>New species of <italic>Madurella</italic>, causative agents of black-grain mycetoma</article-title>. <source>J Clin Microbiol</source>. <year>2012</year>;<volume>50</volume>(<issue>3</issue>):<fpage>988</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">22205798</pub-id></mixed-citation></ref><ref id="bib37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Ahmed</surname>
<given-names>SA</given-names>
</string-name>, <string-name><surname>Kloezen</surname><given-names>W</given-names></string-name>, <string-name><surname>Fahal</surname><given-names>AH</given-names></string-name><etal>et al.</etal></person-group>
<article-title>In vitro interaction of currently used azoles with terbinafine against <italic>Madurella mycetomatis</italic></article-title>. <source>Antimicrob Agents Chemother</source>. <year>2015</year>;<volume>59</volume>(<issue>2</issue>):<fpage>1373</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">25487799</pub-id></mixed-citation></ref><ref id="bib38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Borman</surname>
<given-names>AM</given-names>
</string-name>, <string-name><surname>Desnos-Ollivier</surname><given-names>M</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>CK</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Novel taxa associated with human fungal black-grain mycetomas: <italic>Emarellia grisea</italic> gen. nov., sp. nov., and <italic>Emarellia paragrisea</italic> sp. nov</article-title>. <source>J Clin Microbiol</source>. <year>2016</year>;<volume>54</volume>(<issue>7</issue>):<fpage>1738</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">27076666</pub-id></mixed-citation></ref><ref id="bib39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Fothergill</surname>
<given-names>AW</given-names>
</string-name>, <string-name><surname>Rinaldi</surname><given-names>MG</given-names></string-name>, <string-name><surname>Sutton</surname><given-names>DA</given-names></string-name></person-group>. <article-title>Antifungal susceptibility testing of <italic>Exophiala</italic> spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole</article-title>. <source>Med Mycol</source>. <year>2009</year>;<volume>47</volume>(<issue>1</issue>):<fpage>41</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">19107637</pub-id></mixed-citation></ref><ref id="bib40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>van de Sande</surname>
<given-names>WWJ</given-names>
</string-name>, <string-name><surname>Fahal</surname><given-names>AH</given-names></string-name>, <string-name><surname>Bakker-Woudenberg</surname><given-names>IAJM</given-names></string-name><etal>et al.</etal></person-group>
<article-title>
<italic>Madurella mycetomatis</italic> is not susceptible to the echinocandin class of antifungal agents</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2010</year>;<volume>54</volume>(<issue>6</issue>):<fpage>2738</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">20350944</pub-id></mixed-citation></ref><ref id="bib41"><label>41</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><collab>Drugs for Neglected Diseases Initiative</collab></person-group>. <source>Fosravuconazole</source>. <comment>Available from</comment>: <comment><ext-link ext-link-type="uri" xlink:href="http://www.dndi.org/diseases-projects/portfolio/fosravuconazole/">http://www.dndi.org/diseases-projects/portfolio/fosravuconazole/</ext-link></comment>. <comment>[Accessed April 24, 2020]</comment>.</mixed-citation></ref><ref id="bib42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Venugopal</surname>
<given-names>PV</given-names>
</string-name>, <string-name><surname>Venugopal</surname><given-names>TV</given-names></string-name>, <string-name><surname>Ramakrishna</surname><given-names>ES</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Antimycotic susceptibility testing of agents of black grain eumycetoma</article-title>. <source>J Med Vet Mycol</source>. <year>1993</year>;<volume>31</volume>(<issue>2</issue>):<fpage>161</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">8389847</pub-id></mixed-citation></ref><ref id="bib43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Nyuykonge</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Klaassen</surname><given-names>CHW</given-names></string-name>, <string-name><surname>Zandijk</surname><given-names>WHA</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Diagnostic implications of mycetoma derived from <italic>Madurella pseudomycetomatis</italic> isolates from Mexico</article-title>. <source>J Eur Acad Dermatol Venereol</source>. <year>2020</year>;<volume>34</volume>(<issue>8</issue>):<fpage>1828</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">32233084</pub-id></mixed-citation></ref><ref id="bib44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Walsh</surname>
<given-names>TJ</given-names>
</string-name>, <string-name><surname>Peter</surname><given-names>J</given-names></string-name>, <string-name><surname>McGough</surname><given-names>DA</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Activities of amphotericin B and antifungal azoles alone and in combination against <italic>Pseudallescheria boydii</italic></article-title>. <source>Antimicrob Agents Chemother</source>. <year>1995</year>;<volume>39</volume>(<issue>6</issue>):<fpage>1361</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">7574531</pub-id></mixed-citation></ref><ref id="bib45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Gonzalez</surname>
<given-names>GM</given-names>
</string-name>, <string-name><surname>Tijerina</surname><given-names>R</given-names></string-name>, <string-name><surname>Najvar</surname><given-names>LK</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Activity of posaconazole against <italic>Pseudallescheria boydii</italic>: in vitro and in vivo assays</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2003</year>;<volume>47</volume>(<issue>4</issue>):<fpage>1436</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">12654687</pub-id></mixed-citation></ref><ref id="bib46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Venugopal</surname>
<given-names>PV</given-names>
</string-name>, <string-name><surname>Venugopal</surname><given-names>TV</given-names></string-name></person-group>. <article-title>Treatment of eumycetoma with ketoconazole</article-title>. <source>Australas J Dermatol</source>. <year>1993</year>;<volume>34</volume>(<issue>1</issue>):<fpage>27</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">8240184</pub-id></mixed-citation></ref><ref id="bib47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Gulmez</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Dogan</surname><given-names>O</given-names></string-name>, <string-name><surname>Boral</surname><given-names>B</given-names></string-name><etal>et al.</etal></person-group>
<article-title>In vitro activities of antifungal drugs against environmental <italic>Exophiala</italic> isolates and review of the literature</article-title>. <source>Mycoses</source>. <year>2018</year>;<volume>61</volume>(<issue>8</issue>):<fpage>561</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">29611230</pub-id></mixed-citation></ref><ref id="bib48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Badali</surname>
<given-names>H</given-names>
</string-name>, <string-name><surname>Najafzadeh</surname><given-names>MJ</given-names></string-name>, <string-name><surname>van Esbroeck</surname><given-names>M</given-names></string-name><etal>et al.</etal></person-group>
<article-title>The clinical spectrum of <italic>Exophiala jeanselmei</italic>, with a case report and in vitro antifungal susceptibility of the species</article-title>. <source>Med Mycol</source>. <year>2010</year>;<volume>48</volume>(<issue>2</issue>):<fpage>318</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">19642051</pub-id></mixed-citation></ref><ref id="bib49"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Andes</surname>
<given-names>D</given-names>
</string-name>, <string-name><surname>Pascual</surname><given-names>A</given-names></string-name>, <string-name><surname>Marchetti</surname><given-names>O</given-names></string-name></person-group>. <article-title>Antifungal therapeutic drug monitoring: established and emerging indications</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2009</year>;<volume>53</volume>(<issue>1</issue>):<fpage>24</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">18955533</pub-id></mixed-citation></ref><ref id="bib50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Dolton</surname>
<given-names>MJ</given-names>
</string-name>, <string-name><surname>Perera</surname><given-names>V</given-names></string-name>, <string-name><surname>Pont</surname><given-names>LG</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2014</year>;<volume>58</volume>(<issue>1</issue>):<fpage>48</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">24126579</pub-id></mixed-citation></ref><ref id="bib51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Eadie</surname>
<given-names>K</given-names>
</string-name>, <string-name><surname>Parel</surname><given-names>F</given-names></string-name>, <string-name><surname>Helvert-van Poppel</surname><given-names>M</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Combining two antifungal agents does not enhance survival of <italic>Galleria mellonella</italic> larvae infected with <italic>Madurella mycetomatis</italic></article-title>. <source>Trop Med Int Health</source>. <year>2017</year>;<volume>22</volume>(<issue>6</issue>):<fpage>696</fpage>&#x02013;<lpage>702</lpage>.<pub-id pub-id-type="pmid">28342219</pub-id></mixed-citation></ref><ref id="bib52"><label>52</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><string-name>
<surname>Abd Algaffar</surname>
<given-names>SO</given-names>
</string-name>, <string-name><surname>Katalin</surname><given-names>V</given-names></string-name>, <string-name><surname>Hohmann</surname><given-names>J</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Metabolomic approach to tap the potential of essential oils against <italic>Madurella mycetomatis</italic> &#x02013; one of the most neglected fungal infections</article-title>. <comment>Presented at the 20th</comment><source>Congress of the International Society for Human and Animal Mycosis</source>, <publisher-loc>Amsterdam</publisher-loc>, <comment>30 June&#x02013;4 July</comment><year>2018</year>.</mixed-citation></ref><ref id="bib53"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>van de Sande</surname>
<given-names>WW</given-names>
</string-name>, <string-name><surname>van Vianen</surname><given-names>W</given-names></string-name>, <string-name><surname>ten Kate</surname><given-names>M</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Amphotericin B but not itraconazole is able to prevent grain formation in experimental <italic>Madurella mycetomatis</italic> mycetoma in mice</article-title>. <source>Br J Dermatol</source>. <year>2015</year>;<volume>173</volume>(<issue>6</issue>):<fpage>1561</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">26150103</pub-id></mixed-citation></ref><ref id="bib54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Murray</surname>
<given-names>IG</given-names>
</string-name>, <string-name><surname>Colichon</surname><given-names>H</given-names></string-name></person-group>. <article-title>Chemotherapy of maduromycosis. I. Preliminary experiments with diamidinodi-phenylamine dihydrochloride and amphotericin B in vivo and in vitro</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>1962</year>;<volume>56</volume>:<fpage>156</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">14477462</pub-id></mixed-citation></ref><ref id="bib55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Kloezen</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>Parel</surname><given-names>F</given-names></string-name>, <string-name><surname>Bruggemann</surname><given-names>R</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Amphotericin B and terbinafine but not the azoles prolong survival in <italic>Galleria mellonella</italic> larvae infected with <italic>Madurella mycetomatis</italic></article-title>. <source>Med Mycol</source>. <year>2018</year>;<volume>56</volume>(<issue>4</issue>):<fpage>469</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">28992315</pub-id></mixed-citation></ref><ref id="bib56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Murray</surname>
<given-names>JG</given-names>
</string-name>, <string-name><surname>Spooner</surname><given-names>ET</given-names></string-name>, <string-name><surname>Walker</surname><given-names>J</given-names></string-name></person-group>. <article-title>Experimental infection of mice with <italic>Madurella mycetomi</italic></article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>1960</year>;<volume>54</volume>(<issue>4</issue>):<fpage>335</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">14425433</pub-id></mixed-citation></ref><ref id="bib57"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Ahmed</surname>
<given-names>AO</given-names>
</string-name>, <string-name><surname>van Vianen</surname><given-names>W</given-names></string-name>, <string-name><surname>ten Kate</surname><given-names>MT</given-names></string-name><etal>et al.</etal></person-group>
<article-title>A murine model of <italic>Madurella mycetomatis</italic> eumycetoma</article-title>. <source>FEMS Immunol Med Microbiol</source>. <year>2003</year>;<volume>37</volume>(<issue>1</issue>):<fpage>29</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">12770757</pub-id></mixed-citation></ref><ref id="bib58"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Kloezen</surname>
<given-names>W</given-names>
</string-name>, <string-name><surname>van Helvert-van Poppel</surname><given-names>M</given-names></string-name>, <string-name><surname>Fahal</surname><given-names>AH</given-names></string-name><etal>et al.</etal></person-group>
<article-title>A <italic>Madurella mycetomatis</italic> grain model in <italic>Galleria mellonella</italic> larvae</article-title>. <source>PLoS Negl Trop Dis</source>. <year>2015</year>;<volume>9</volume>(<issue>7</issue>):<fpage>e0003926</fpage>.<pub-id pub-id-type="pmid">26173126</pub-id></mixed-citation></ref><ref id="bib59"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>van de Sande</surname>
<given-names>WW</given-names>
</string-name>, <string-name><surname>de Kat</surname><given-names>J</given-names></string-name>, <string-name><surname>Coppens</surname><given-names>J</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Melanin biosynthesis in <italic>Madurella mycetomatis</italic> and its effect on susceptibility to itraconazole and ketoconazole</article-title>. <source>Microbes Infect</source>. <year>2007</year>;<volume>9</volume>(<issue>9</issue>):<fpage>1114</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">17644456</pub-id></mixed-citation></ref><ref id="bib60"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Ibrahim</surname>
<given-names>AI</given-names>
</string-name>, <string-name><surname>El Hassan</surname><given-names>AM</given-names></string-name>, <string-name><surname>Fahal</surname><given-names>A</given-names></string-name><etal>et al.</etal></person-group>
<article-title>A histopathological exploration of the <italic>Madurella mycetomatis</italic> grain</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>3</issue>):<fpage>e57774</fpage>.<pub-id pub-id-type="pmid">23483927</pub-id></mixed-citation></ref><ref id="bib61"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Findlay</surname>
<given-names>GH</given-names>
</string-name>, <string-name><surname>Vismer</surname><given-names>HF</given-names></string-name></person-group>. <article-title>Black grain mycetoma. Atomic absorption and spark source mass spectrophotometry of the tissue grain in <italic>Madurella mycetomi</italic> infection</article-title>. <source>Br J Dermatol</source>. <year>1977</year>;<volume>97</volume>(<issue>5</issue>):<fpage>497</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">588463</pub-id></mixed-citation></ref><ref id="bib62"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Findlay</surname>
<given-names>GH</given-names>
</string-name>, <string-name><surname>Vismer</surname><given-names>HF</given-names></string-name></person-group>. <article-title>Black grain mycetoma. A study of the chemistry, formation and significance of the tissue grain in <italic>Madurella mycetomi</italic> infection</article-title>. <source>Br J Dermatol</source>. <year>1974</year>;<volume>91</volume>(<issue>3</issue>):<fpage>297</fpage>&#x02013;<lpage>303</lpage>.<pub-id pub-id-type="pmid">4139964</pub-id></mixed-citation></ref><ref id="bib63"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Wethered</surname>
<given-names>DB</given-names>
</string-name>, <string-name><surname>Markey</surname><given-names>MA</given-names></string-name>, <string-name><surname>Hay</surname><given-names>RJ</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Ultrastructural and immunogenic changes in the formation of mycetoma grains</article-title>. <source>J Med Vet Mycol</source>. <year>1987</year>;<volume>25</volume>(<issue>1</issue>):<fpage>39</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">2437279</pub-id></mixed-citation></ref><ref id="bib64"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Reichhardt</surname>
<given-names>C</given-names>
</string-name>, <string-name><surname>Stevens</surname><given-names>DA</given-names></string-name>, <string-name><surname>Cegelski</surname><given-names>L</given-names></string-name></person-group>. <article-title>Fungal biofilm composition and opportunities in drug discovery</article-title>. <source>Future Med Chem</source>. <year>2016</year>;<volume>8</volume>(<issue>12</issue>):<fpage>1455</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">27485639</pub-id></mixed-citation></ref><ref id="bib65"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Gao</surname>
<given-names>L</given-names>
</string-name>, <string-name><surname>Jiang</surname><given-names>S</given-names></string-name>, <string-name><surname>Sun</surname><given-names>Y</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Evaluation of the effects of photodynamic therapy alone and combined with standard antifungal therapy on planktonic cells and biofilms of <italic>Fusarium</italic> spp. and <italic>Exophiala</italic> spp</article-title>. <source>Front Microbiol</source>. <year>2016</year>;<volume>7</volume>:<fpage>617</fpage>.<pub-id pub-id-type="pmid">27199946</pub-id></mixed-citation></ref><ref id="bib66"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Sun</surname>
<given-names>Y</given-names>
</string-name>, <string-name><surname>Gao</surname><given-names>L</given-names></string-name>, <string-name><surname>He</surname><given-names>C</given-names></string-name><etal>et al.</etal></person-group>
<article-title>In vitro interactions between IAP antagonist AT406 and azoles against planktonic cells and biofilms of pathogenic fungi <italic>Candida albicans</italic> and <italic>Exophiala dermatitidis</italic></article-title>. <source>Med Mycol</source>. <year>2018</year>;<volume>56</volume>(<issue>8</issue>):<fpage>1045</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">29346584</pub-id></mixed-citation></ref><ref id="bib67"><label>67</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><collab>European Committee on Antimicrobial Susceptibility Testing</collab></person-group>. <source>Breakpoint tables for interpretation of MICs for antifungal agents, version 10.0, valid from 2020-02-04</source>. <comment>Available from</comment>: <comment><ext-link ext-link-type="uri" xlink:href="https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Clinical_breakpoints/AFST_BP_v10.0_200204.pdf">https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Clinical_breakpoints/AFST_BP_v10.0_200204.pdf</ext-link></comment>. <comment>[Accessed April 24, 2020]</comment>.</mixed-citation></ref><ref id="bib68"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Zein</surname>
<given-names>HA</given-names>
</string-name>, <string-name><surname>Fahal</surname><given-names>AH</given-names></string-name>, <string-name><surname>Mahgoub</surname><given-names>ES</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Predictors of cure, amputation and follow-up dropout among patients with mycetoma seen at the Mycetoma Research Centre, University of Khartoum, Sudan</article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>2012</year>;<volume>106</volume>(<issue>11</issue>):<fpage>639</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">22854685</pub-id></mixed-citation></ref><ref id="bib69"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Mahgoub</surname>
<given-names>ES</given-names>
</string-name>, <string-name><surname>Gumaa</surname><given-names>SA</given-names></string-name></person-group>. <article-title>Ketoconazole in the treatment of eumycetoma due to <italic>Madurella mycetomii</italic></article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>1984</year>;<volume>78</volume>(<issue>3</issue>):<fpage>376</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">6087513</pub-id></mixed-citation></ref><ref id="bib70"><label>70</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>Fahal</surname>
<given-names>AH</given-names>
</string-name>, <string-name><surname>Rahman</surname><given-names>IA</given-names></string-name>, <string-name><surname>El-Hassan</surname><given-names>AM</given-names></string-name><etal>et al.</etal></person-group>
<article-title>The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to <italic>Madurella mycetomatis</italic></article-title>. <source>Trans R Soc Trop Med Hyg</source>. <year>2011</year>;<volume>105</volume>(<issue>3</issue>):<fpage>127</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">21247608</pub-id></mixed-citation></ref><ref id="bib71"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><string-name>
<surname>N'Diaye</surname>
<given-names>B</given-names>
</string-name>, <string-name><surname>Dieng</surname><given-names>MT</given-names></string-name>, <string-name><surname>Perez</surname><given-names>A</given-names></string-name><etal>et al.</etal></person-group>
<article-title>Clinical efficacy and safety of oral terbinafine in fungal mycetoma</article-title>. <source>Int J Dermatol</source>. <year>2006</year>;<volume>45</volume>(<issue>2</issue>):<fpage>154</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">16445509</pub-id></mixed-citation></ref></ref-list></back></article>